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Abstract
Toward Fullerene Immunotherapy with Water-Soluble Paclitaxel-Fullerene Conjugates
by
Christopher Scott Berger
For the first time, two distinct, well-characterized water-soluble 
chemotherapeutic-C60 conjugates have been constructed for targeted drug delivery of 
paclitaxel to cancer cells.
In vitro work was carried out in two stages to determine IC50 values of the 
conjugates. Primarily, work was performed on A375m melanoma, T-24 bladder 
carcinoma, and Hep 3B hepatocellular carcinoma cell lines. In these studies, it was 
revealed that  although the first compound, a paclitaxel-2’-succinate-C60 derivative, 
experienced a dramatic loss of cytotoxicity in comparison to paclitaxel, the second 
derivative, utilizing a poly(ethylene glycol) linker, demonstrated over 10× better 
cytotoxicity than paclitaxel itself.
Additional in vitro studies were conducted to create a chemotherapeutic-fullerene-
monoclonal antibody immunoconjugate for targeted drug delivery. Endohedral 
Gd@C60(OH)x was associated to antibodies via supramolecular forces instead of covalent 
chemical bonding. ELISA assays showed that Gd@C60(OH)x-mAb immunoconjugates 
retain binding specificity, and inductively coupled plasma mass spectrometry (ICP-MS) 
demonstrated selective internalization of the immunoconjugate into targeted cells. 
Subsequent studies utilized a similar strategy of fullerene-antibody association to 
construct a immunoconjugate for targeted chemotherapy with a water-soluble 
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paclitaxel-2’-succinate-C60 derivative. While cytotoxicity was measurable, no discernible 
advantage was seen by the targeted C60-(ZME-018) immunoconjugate over a MuIgG 
control, thus leaving room for further refinement of the approach for targeted cancer 
therapy.
In vivo work, using the potent paclitaxel-poly(ethylene glycol)-C60 derivative in a 
murine model, demonstrated success by producing a similar capacity  for tumor-reduction 
compared to the FDA-approved drug Abraxane®, without associated weight-loss in 
animals seen for Abraxane.
A major contribution of this work is the progress made toward development of 
Fullerene Immunotherapy (FIT) and the potential translation of FIT into the clinic. 
Having demonstrated the potent, improved cytotoxicity of a paclitaxel-C60 conjugate, the 
next step in the development of FIT is the successful construction of a therapeutic 
fullerene-antibody  immunoconjugate. The results documented in this work have now 
shifted the onus of FIT from a theoretical concept to a realistic goal awaiting final 
developmental refinement.
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Chapter 1
Introduction
1.1 Background
Since the initial discovery  of buckminsterfullerenes (C60) in 19851 and carbon 
nanotubes in 1991,2 the unique chemical and physical properties of carbon nanostructures 
have ignited the field of nanotechnology and attracted the attention of researchers 
focusing on applications ranging from superconductivity  to chemical sensors,3 with 
medical applications being one of the most prominent areas of study.4
Although their toxicity is still under debate, carbon nanostructures appear to be 
ideal scaffolds for medical applications. Initially, their low solubility  in aqueous solution 
limited their use for biomedical purposes, but extensive derivatization methods have 
resulted in the facile availability of aqueous fullerene derivatives.5,6,7 Properly  derivatized 
carbon nanostructures appear not to be intrinsically immunogenic (although more study is 
needed), stable, and are eventually  excreted from mammals,8,9 making them an ideal 
biological scaffold for medical materials. Attaching hydrophilic substituents to a fullerene 
core not only provides water solubility, but also controls and modifies the biological 
activity of fullerene derivatives.10 Additionally, carbon nanomaterials can be internally 
loaded, either during initial synthesis (fullerenes) or in post-production steps (carbon 
nanotubes), with materials possessing useful properties for therapy or diagnosis, such as 
radionuclides for α-radiotherapy11 or Gd3+ ions for MRI.12 New potential pharmaceuticals 
derived from C60 show promising biological profiles and efficacies as HIV-1 protease 
inhibitors,13 antioxidants,14 bone-vectoring agents,15 sensitizers for photodynamic 
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therapy,16 MRI contrast agents,17 transfection agents,18 x-ray  contrast agents,19 and slow-
release systems for liposome aerosol delivery.20
1.2 Fullerene HIV-1 Protease Inhibitors
The hydrophobicity of C60, while a problem for many biological applications, also 
makes it a potential inhibitor of enzymes with hydrophobic active sites, such as HIV-1 
protease. Molecular modeling and calculations show C60 to fit into the catalytic cavity  of 
HIV-1 protease,21 while experimental studies show many  C60 derivatives to demonstrate 
anti-HIV activity with EC50 values within the range of 0.9-2.9 µM.22 Due to the 
hydrophobic amino acids lining the HIV-1 protease active site, presumably hydrophobic 
interactions are the main force behind C60/HIV-1 protease association. Additional 
cycloaddition functionalization of fullerenes with positively charged quaternary amines 
further increased inhibition binding and reduced EC50 to values in the high nanomolar 
range, possibly by strengthening electrostatic interactions with negatively-charged 
catalytic aspartic acids (Asp 25 and Asp 125) lining the active site.23
1.3 Fullerene Antioxidant Properties
Due to its electron-accepting nature, C60 is highly reactive towards free radicals.24 
This reactivity assigns C60 compounds a prominent role in the possible prevention and 
treatment of various neurological diseases such as Parkinson’s disease, Alzheimer’s 
disease, senility, and schizophrenia, in which the role of free radical production has only 
recently  come into focus.25,26,27 In particular, the production of superoxides and hydroxyl 
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free radicals plays a key role in aging, raising the potential for fullerenes as important 
inhibitors for aging.  Recently, Baati et al. administered oral solutions of C60 in olive oil 
(0.8 mg/mL) at reiterated doses (1.7 mg/kg) to rats.14 The control group (water) had a 
median lifespan of 22 months, while the group receiving olive oil had a slightly longer 
median lifespan of 26 months. However, the group receiving C60/olive oil suspension 
survived for 42 months, a 90.9% increase in lifespan over the control group. Additionally, 
oxidative stress was studied in the rats by intraperitoneal injection of CCl4, a potent 
hepatotoxin activated by mitochondria metabolism to form trichloromethyl free radical 
(CCl3•). After administration, the rats treated with the C60/olive oil suspension showed 
significantly improved recovery rates over the water and olive oil controls, demonstrating 
the potent antioxidant activity of C60 in vivo.
1.4 Singlet Oxygen Applications of Fullerenes
Paradoxically, while C60 shows promising activity as a quencher of reactive 
radical species, its long absorption wavelength, long-lived triplet excited state and high 
quantum yield also make it  an ideal substrate for generating reactive oxygen species such 
as singlet oxygen (1O2) and superoxide (O2-). Supercoiled, covalently  closed, helical 
pBR322 plasmid DNA (Form I), in the presence of C60 and visible-light irradiation 
became open circular, nicked DNA (Form II), conclusively  indicating biological damage, 
while C60-incubation without irradiation showed no cleavage whatsoever.28 Additionally, 
HeLa S3 cells incubated with a series of C60-carboxylic acid derivatives showed 
significant growth inhibition after two one hour visible light irradiations. No activity  in 
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HeLa cells was observed from any  C60 derivatives in the dark.29 More recently, C60 was 
covalently conjugated with polyethylene glycol (PEG) for water solubility, whereupon 
the terminal PEG hydroxyl was esterified to the commercially-used octadentate ligand 
diethylene triamine pentaacetic acid (DTPA). With introduction of Gd3+ into the DTPA 
ligand and intravenous administration into tumor-bearing mice, the C60-PEG-Gd complex 
formed a theranostic treatment demonstrating comparable relaxivity with the clinical 
standard MRI contrast agent Magnevist® and significant anti-tumor activity  with visible 
light irradiation for 10 minutes.30 This ability of irradiated C60 derivatives to induce 
DNA cleavage in vitro and in vivo results in a relatively high cytotoxicity  for a material 
normally considered to be biologically inert, which suggests possibilities for new 
applications.
On a different note, a new direction of C60 free radical generation is being taken 
toward industrial purification of drinking water, where singlet oxygen and other free 
radical species are generated in situ to eliminate both organic molecules and 
microorganisms.31,32 By immobilizing polyadduct amine-functionalized fullerene (amino-
C60) on silica, 1O2 generation actually became more efficient, an effect hypothesized by 
the investigators to be most likely attributable to better dispersion in solution and 
decreased C60 aggregation/agglomeration. Hexakis-adduct, amino-C60 silica demonstrated 
the most  1O2 activity, rapidly photodegrading both ranitidine and cimetidine in visible 
light at concentrations of 0.1 mmol/gram silica. In addition to organic compound 
degradation, micromolar concentrations of photoirradiated amino-C60 on silica inhibited 
growth of E. Coli, clearly showing the potential of C60 for antiseptic applications.
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1.5 Fullerene Contrast Agents for Magnetic Resonance Imaging
Shortly after the first evidence of buckminsterfullerenes appeared, following on 
its heels was the idea of encapsulating metal ions within its carbon cage to form 
endohedral metallofullerenes.33 By sequestering metal ions with beneficial physical 
properties, but  deleterious chemical properties, inside a biologically  impenetrable carbon 
cage, these fullerenes poses a major advantage over traditional metal chelates and show 
significant potential as medical agents. Gadolinium(III) ion, the clinical standard for T1-
weighted MRI contrast enhancement, possesses seven unpaired f electrons, making it 
highly  paramagnetic and effective at reducing T1 (longitudinal) and T2 (transverse) 
relaxation times in surrounding protons. Gd@C60[C(COOH)2]10, a water-soluble carboxyl 
malonate Gd@C60 derivative, demonstrated proton relaxivity comparable to that of the 
Gd3+ chelate MRI contrast agents,34 while Gd@C82(OH)n fullerenols displayed proton 
relaxivities 20 times higher than clinically used contrast agents.35,36
Finally, posing perhaps the most important advance in fullerene MRI contrast 
agents are trimetallic nitride templated (TNT) endohedral gadolinium fullerenes 
( G d 3 N @ C 8 0 ) . R e c e n t l y , a w a t e r - s o l u b l e T N T d e r i v a t i v e 
(Gd3N@C80(OH)~26(CH2CH2COOH)~16) was reported with T1 and T2 relaxivities almost 
50 times those of clinical contrast agents.37 With the added advantage of three gadolinium 
ions per fullerene, these compounds are produced in relatively high yields and pose what 
could be a promising step toward the production of a fullerene-based clinical agent.
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1.6 Fullerene Liposomes
Liposomes are artificially-prepared vesicles composed of a hydrophobic-
hydrophilic bilayer, used as a vehicle to administer pharmaceuticals. Pharmaceutical 
liposomes utilize the membranes to encapsulate a hydrophobic region containing 
therapeutic molecules; upon contact with other bilayers, such as those found in the cell 
membrane, a liposome’s lipid bilayer can fuse, thus delivering its contents to its sites of 
action.
The versatile chemistry and natural hydrophobicity of C60 make it  an excellent 
candidate for liposomal study. In one study, Partha et al.38 built on the previous research 
of Hirsch and co-workers,39 to construct amphiphilic fullerenes, with a single hydrophilic 
malonate dendrimer unit, while five other octahedral positions on the fullerene occupied 
by hydrophobic aliphatic malonates. By sonicating these fullerenes with paclitaxel in 10 
mM citrate buffer (pH: 7.4) for 1 minute, paclitaxel-containing spherical structures 
(referred to as “buckysomes”) of 100-200 nm were formed. In vitro testing with MCF-7 
breast cancer cells showed the buckysomes to have chemotherapeutic potency on the 
same order of Abraxane®, a clinically-used protein-bound paclitaxel formulation, in 
which paclitaxel is bound to albumin for use as a water-soluble delivery vehicle.40
Another avenue toward fullerene-liposome delivery of paclitaxel was taken by 
Zakharian et al. through direct  covalent conjugation of paclitaxel with C60.20 By 
synthesizing and characterizing a discrete, homogeneous, fullerene-paclitaxel compound, 
these researchers were able to construct stable dilauroylphosphatidylcholine (DLPC) 
liposomes, with a mean diameter of 2.77 µm, for potential aerosol delivery  to lung 
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carcinomas. IC50 values of the fullerene-paclitaxel-DLPC and fullerene-DLPC liposomes 
were respectively 410 and 253 nM, demonstrating a marked decrease in potency upon 
conjugation of the paclitaxel. However, with the promise of lung-directed delivery, the 
potential of fullerenes for use as a drug delivery vector appears promising.
1.7 Water-Soluble Fullerenes for Chemotherapy
By conjugating the anthracycline chemotherapeutic, doxorubicin, to water-soluble 
fullerenols (C60(OH)x), via a carbamate linker, Chaudhuri et al. constructed a material 
that, in vivo, was successful at significantly reducing the tumor volume of B16/F10 
melanomas.41 Additionally, measured stress on the murine subjects showed little loss in 
heart or spleen mass, compared to the control PBS solution, and a significant 
improvement over the naked doxorubicin, which causes significant weight loss in 
subjects.
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Chapter 2
Design of a Water-Soluble C60- Paclitaxel 
Conjugate
2.1 Targeted Therapeutics
The goal of targeted therapeutics has been one of the holy grails of modern 
medicine for over 100 years. At the dawn of immunology, modern passive immunization 
began in two stages.  In 1888, Émile Roux, Emil von Behring and Kitasato Shibasaburo, 
of the Pasteur Institute immunized lab animals with heat-attenuated forms of diptheria 
and tetanus, which contained the bacterial toxins, but no live specimens.  Collected sera 
from these animals was injected into infected animals with manifested symptoms, only to 
result in sera antitoxins relieving patient symptoms and eventually  leading to recovery 
from infections that would previously have been fatal.
 Behring’s “serum therapy” eventually reached mass-production in horses and 
first saw treatment in humans in 1896, becoming the first  immunity-based treatment for 
infectious disease since Jenner’s smallpox vaccine developed over a century before. In 
the wake of this revolutionary therapy, Paul Ehrlich, who had assisted von Behring, noted 
that prokaryotic cell walls of certain infection bacterial strains were susceptible to 
staining from dyes (a precursor to Gram staining). This led Ehrlich to then infer that if 
dyes could target and bind to cell walls, it must be possible to find toxic materials that 
would target  foreign bacteria in an infected patient over native tissue. This theoretical 
“magic bullet” would target problematic cells in a patient with no peripheral damage, 
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producing little or no side effects. Ehrlich, thus, had made a prediction that became the 
goal for medical treatment over the next century.
Ehrlich’s concept of a magic bullet persists to this day. Current estimates are that 
only 1 in 104 to 1 in 105 of an administered pharmaceutical reaches its intended 
destination,42 so even a small increase in the gradient of therapy delivered to target could 
produce significant improvements in patient outcome. The simple goal of targeted 
therapies is to produce high concentrations of the therapeutic agent in the appropriate 
biological area, thus reducing patient side effects while allowing higher pharmaceutical 
doses to be administered. The development of cell-targeted agents for imaging and 
therapeutic applications in medicine is accelerating.
As the search continues to develop  new therapies to treat cancer, research 
progresses to find a modality selective enough to chaperone pharmaceuticals to targeted 
cells, yet versatile enough to incorporate many different classes of molecules for delivery. 
To accomplish this goal, cytokines, growth factors, kinase inhibitors and monoclonal 
antibodies (mAbs) all show promise for their ability  to deliver payloads to the cell surface 
and into the cytoplasm of targeted cancer cells.43 Using a patient’s own cellular 
identification system to target cancer with immunoconjugates is evolving into a potent 
anticancer therapy in personalized medicine.44,45,46 To date, numerous attempts have 
already been made at attempting to provide cellular targeting by attachment of paclitaxel 
to mAbs,47,48 tumor-recognizing peptides49 and hyaluronic acid (a linear polysaccharide 
overexpressed at sites of tumor attachment)50 in order to select rapidly growing cancer 
cells over an organism’s normal, healthy cells. Currently, however, the most versatile and 
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successful class of agents to show targeting capabilities for specific cancers are mAbs. 
 Three immunoconjugates are currently  FDA-approved for clinical use. Two 
murine mAbs immunoconjugates, ibritumomab tiuxetan and tositumomab, act as direct 
therapy to target the B-cell glycoprotein CD20 to treat non-Hodgkin’s lymphomas. Once 
they  have targeted lymphoma cells, radionuclides chelated to the antibody release β- 
particles to directly kill cancer cells.51,52,53,54 A third covalently conjugated therapy, 
brentuximab vedotin, received approval in August 2011 for treatment of anaplastic large 
cell lymphoma (ALCL) and Hodgkin’s lymphoma. Brentuximab vedotin targets the 
tumor cell marker CD30, and once internalized into tumor cells, releases monomethyl 
auristatin E, an antineoplastic and antimitotic agent that blocks tubulin polymerization.55 
Interestingly, gemtuzumab ozogamicin, an immunoconjugate used in the treatment of 
acute myelogenous leukemia, was withdrawn from clinical use in June 2010 when human 
trials showed the drug actually increased patient death and proved no benefit over 
conventional cancer therapies.56 If anything, the withdrawl of gemtuzumab ozogamicin 
highlights both the challenge of development and increasing demand for targeted 
therapies, with over a dozen other antibody-drug conjugate (ADC) therapies already in 
clinical trials. For optimal efficacy, these immunoconjugates must internalize effectively 
within target cells after binding to the cell-surface antigen.
By using fullerenes as a novel delivery vehicle for paclitaxel, the potential for a 
new modality of targeted therapy is introduced. Fullerene immunotherapy (FIT) should 
provide a versatile tool capable of combining different potent pharmaceuticals in high 
ratios with different antibodies to custom make potent cocktails to attack cancer.  A new 
10
strategy is being capitalized on by  combining two current drug delivery methods: 
fullerenes as a delivery  vector and ester conjugations. As new technologies have 
increased the diversity and reduced the cost of clinical antibodies, research is heavily 
underway to use antibodies as delivery vectors.  
By using an ester bond to attach paclitaxel to water-soluble C60 and then non-
covalently “associating” the functionalized fullerene with an antibody, we are seeking to 
create an entirely  new, multifunctional moiety  for drug delivery with a higher 
therapy:mAb ratio than is currently available.  The eventual goal is that upon clinical 
administration of a paclitaxel-C60-mAb immunoconjugate, antibody  internalization will 
occur into the cell, resulting in cellular digestion of the antibody and releasing paclitaxel-
C60 into the cytosol.  Ubiquitous cellular esterases, on which many cell labeling and drug 
delivery techniques already  rely, will release the paclitaxel freeing it for therapeutic 
activity.
2.2 Paclitaxel Structure and Activity
Paclitaxel (Bristol-Myers Squibb Brand Name: Taxol®) is a potent cytotoxic and 
antimitotic natural diterpenoid first discovered and isolated from the Pacific yew, Taxus 
brevifolia, in 1967 by  Drs. Monroe E. Wall and Mansukh Wani of the Research Triangle 
Institute during a systematic screening of materials for their pharmacological properties.57 
Although initial anticancer properties in clinical trials were promising, early  studies were 
limited by the low natural abundance of paclitaxel (1.2×103 kg of yew bark yielding only 
10 g of actual paclitaxel)58 and further development languished. In 1989, the National 
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Cancer Institute announced a competition for further development of paclitaxel, and by 
1992, Bristol-Myers Squibb had been selected as the developer and paclitaxel was 
approved and commercialized under the brand name Taxol. With the first total synthesis 
of paclitaxel in 1994, developed by Professor Robert A. Holton at Florida State 
University,59 paclitaxel soon became one of the pharmaceuticals of choice in the 
chemotherapeutic arsenal against cancer. 
Paclitaxel and its FDA-approved analog, docetaxel (Sanofi-Aventis Brand Name: 
Taxotere®), comprise taxanes, one of the most active anticancer agents in clinical use. 
Paclitaxel has FDA-approved indications for use in treatment of metastatic breast cancer, 
HIV-related Kaposi’s sarcoma, and ovarian and non-small cell lung carcinomas. Total 
annual sales for both paclitaxel and docetaxel are approximately  $4 billion per annum, 
though with the recent patent expiration of docetaxel in 2010, this number is expected to 
drop rapidly as it  becomes available generically. By binding to β-tubulin subunits in 
cellular microtubules, paclitaxel promotes assembly and permanent hyperstabilization of 
microtubules, preventing disassembly of the polymeric protein structures composing the 
eukaryotic cellular cytoskeleton.60 As microtubules are essential for mitosis and 
microtubule disassembly is an important process in cell division, this hyperstabilization 
leads to arrested cell division and the cell remains in the G2/M phase of the cell cycle, 
eventually triggering apoptosis.61
In addition to its own inherent cytotoxicity, paclitaxel is able to potently increase 
the susceptibility  of cancer cells to concurrent attacks by DNA-damaging radiation or 
chemotherapeutics, such as cisplatin.62 Although the precise mechanism of action for this 
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effect is not clear, current research indicates that a cell’s G2/M phase is its period of most 
sensitivity to DNA-attack (possibly related to elevated growth as the cell prepares for 
mitosis), and paclitaxel’s arrest  of the cell in this phase may be linked to its radio- and 
chemosensitization properties.63 Despite its impressive therapeutic activities, paclitaxel 
still suffers from significant limitations including multidrug resistance (MDR),64 
extremely low aqueous solubility  and high systemic toxicities (especially  hematologic 
and neurologic). Clinically, paclitaxel is currently administered in the nonionic surfactant 
Cremophor EL®, a polyethoxylated castor oil that is linked to allergic reactions and can 
lead to medium to severe paclitaxel hypersensitivity.65 Paclitaxel’s low solubility profile 
and high systemic toxicity are related, in that poorly soluble therapeutics experience high 
plasma protein binding, generally binding to human serum albumin rather than being 
available to efficiently  traverse cell membranes for their intended goal. As bound 
therapeutics slowly reenter the bloodstream, before they  can assume their intended 
therapeutic role, hepatic metabolism digests them into metabolites that  can cause serious 
side effects. Therefore, a water-soluble prodrug of paclitaxel should be effective in 
providing greater bioavailability and circumventing the drawbacks of Cremophor EL, 
enhancing therapeutic effectiveness.66,67 For this reason, this thesis is predominantly 
concerned with the development and study, both in vitro and in vivo, of a water-soluble 
fullerene-paclitaxel conjugate and its antibody-targeted drug delivery  by fullerene 
immunotherapy (FIT). The general practicality  of FIT has been previously  demonstrated 
by our earlier work.68,69
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For our study, Gd@C60 is conjugated to both a melanoma antibody (ZME-018) 
and a control, non-targeting murine IgG antibody (MuIgG).  ZME-018 targets the gp240 
antigen, found on the surface of >80% of human melanoma cell lines70 and functionalized 
conjugates of ZME-018 have been utilized extensively, with studies ranging from in vitro 
fluorescent studies of surface antigens,71 to 111In-ZME-018 conjugate targeting as both a 
laboratory and clinical in vivo tumor imaging agent.72,73  ZME-018 already  has shown 
great promise in clinical imaging trials74 for the delivery of toxins, cytokines and other 
therapeutic agents to melanoma cells both in vitro and in vivo.75 Immunoconjugates 
containing ZME-018 are known to rapidly internalize into melanoma cells76 and 
effectively localize in vivo into melanoma xenografts after systemic administration and 
demonstrate impressive cytotoxic effects against established tumors in orthotopic models.
77,78 The reliable targeting properties of ZME-018 conjugates and thorough 
characterization in varied immunoconjugate systems make ZME-018 an ideal antibody 
for studying fullerene conjugate delivery.
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Methods and Materials
2.3 Gd@C60(OH)x and C60-Paclitaxel Syntheses
2.3.1 Gd@C60(OH)x Synthesis
Synthesis and characterization of the fullerenes was accomplished using a 
previously  established procedure.12 Since the Gd@C60(OH)x sample used for antibody 
conjugation contained both Gd@C60(OH)x and C60(OH)x species,79 inductively  coupled 
plasma optical emission spectrometry (ICP-OES) from PerkinElmer (Waltham, 
Massachusetts) was used to determine the amount of Gd3+ contained in the product used 
for conjugation, and thus the overall percentage of Gd@C60(OH)x (41.9%).
2.3.2 C60-Paclitaxel Derivative Syntheses
Chemical synthesis of the target C60-Succinate-Paclitaxel (Compound 7) and 
conjugate C60-Poly(ethylene glycol)-Paclitaxel (Compound 9) conjugates each occurred 
in four distinct steps as shown in Schemes 1-4: (1) preparation of the BOC-protected 
amino linker malonate (Compound 1) and reaction with C60 (Compound 2); (2) 
preparation of the acetate-protected, water-solubilizing, serinol malonate (Compound 3), 
reaction with BOC-amino-C60 (Compound 4) and subsequent deprotection of the BOC-
amine and serinol malonate groups (Compound 5); (3) synthesis of paclitaxel-2’-
succinate (Compound 6) and conjugation of the succinate carboxylic acid with the 
fullerene amine (Compound 7); and (4) synthesis of water-soluble paclitaxel-2’-
poly(ethylene glycol) (Compound 8) and conjugation of the terminal carboxylic acid with 
the fullerene amine (Compound 9).  Proton nuclear magnetic resonance spectra were 
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measured on a Bruker (Fremont, California, USA) 500 MHz NMR Spectrometer with 
0.05% (by volume) tetramethylsilane as an internal standard, and processed with 
Nucleomatica iNMR software (Molfetta, Bari, Italia). Fourier-transformed infrared 
spectra were obtained using a Nexus 670 FTIR Thermo-Nicolet (Waltham, 
Massachusetts, USA) spectrometer with a Smart Golden Gate horizontal, single-
reflection ATR in the range of 500–4000 cm−1. Analysis of infrared spectra was provided 
by Advanced Chemistry Development Spectrus Processor (Toronto, Ontario, Canada). 
Mass spectrometry data for water-insoluble compounds were collected using an Autoflex 
MALDI TOF-TOF mass spectrometer (MS Autoflex). Mass spectrometry data for water-
soluble fullerene derivatives were obtained utilizing electrospray ionization time-of-flight 
mass spectrometry (MS micrOTOF ESI).  Both mass spectrometers are Bruker Daltonics, 
Inc. (Billerica, Massachusetts) instruments. Purity and commercial sources of the 
compounds used are shown in Table A1 of the Supplemental Information. Mass 
spectrometry, infrared (IR) spectroscopy and nuclear magnetic resonance (NMR) 
spectroscopy data are given, respectively, in Appendices A2, A3 and A4.
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Figure 2.2: Synthesis scheme of 3’-ethoxycarbonyl-3’-((2-ammoniumethoxy)carbonyl)- 
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Figure 2.3: Synthesis scheme of the serinol-C60-paclitaxel-2’-succinate derivative (7).
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Figure 2.4: Synthesis scheme of the serinol-C60-paclitaxel-2′-poly(ethylene glycol) ester 
derivative (9).
2.3.2.1 2-((Tert-butoxycarbonyl)amino)ethyl ethyl malonate (1)
Tert-butyl (2-hydroxyethyl)carbamate was prepared according to a previously 
published method.80  2-Aminoethanol was suspended in CH2Cl2 and reacted with di-tert-
butyl pyrocarbonate (3% excess) at 25 °C for 16 hours. The product was isolated in vacuo 
and purified using flash chromatography (CHCl3:CH3OH, 2:1; silica: Mallinckrodt, 
60-200 µm particles, 150 Å pore size). Yield: 99%.  2-((Tert-butoxycarbonyl)amino)ethyl 
ethyl malonate was then prepared by  slow addition of ethyl malonyl chloride (25 g, 
0.16 mols) to a dry-ice-cooled solution (-78 °C) of tert-butyl (2-hydroxyethyl)carbamate 
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(25 g, 0.16 mols) and N,N-diisopropylethylamine (DIPEA, 20 g, 0.15 mol) in dry 
methylene chloride (450 mL) under argon. The reaction mixture reached 25 °C and was 
then allowed to react for 16 hours.  The solution was washed twice with water, once with 
NaCl brine, and then dried with Na2SO4. Flash chromatography (hexane:ethyl acetate, 
9:1; silica: Mallinckrodt, 75-250 µm particles, 150 Å pore size) purified the solution 
producing a pale, yellow oil.  Yield: 37 g (0.13 mol, 87%).  MS Autoflex (positive-ion 
mode): calculated mass = 275.14 Da; observed masses = 293.367 Da [M++H2O], 316.703 
Da [M+K+]. NMR (500 MHz, CDCl3, 0.05% (v/v) TMS reference): 1H δ (ppm) = 1.290 
(t, 3H, CH3), 1.439 (s, 9H, C(CH3)3), 3.409 (s, 2H, CH2), 4.209 (q, 2H, CH2CH3), 5.322 
(t, 2H, CH2NH); 13C δ (ppm) = 14.069, 28.357, 39.418, 41.422, 48.963, 61.587, 64.537, 
79.302, 155.939, 166.554.  The mass spectrometry, IR and NMR spectral data are all 
respectively provided in Appendix Figures A2.1, A3.1 and A4.1.
2.3.2.2 3’-Ethoxycarbonyl-3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)-[1,2]
(C60-Ih)[5,6]fullerene (2)
C60 (727 mg, 1.00 mmol) was dissolved in freshly distilled toluene (500 mL) with 
CBr4 (500 mg, 1.49 mmol), and 1 (413 mg, 1.50 mmol).  At 25 °C, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 230 mg, 1.48 mmol) in toluene was added to the 
solution over 1 hour, and the reaction was allowed to proceed for 18 additional hours. 
Flash chromatography (toluene:ethyl acetate, 9:1; silica: Mallinckrodt, 75-250 µm 
particles, 150 Å pore size) isolated the product. Yield: 331.6 mg (33.4 mmol, 33.4%). 
MS Autoflex (positive-ion mode): calculated mass = 993.12 Da; observed mass = 
21
993.197 Da [M+].  NMR (500 MHz, CDCl3, 0.05% (v/v) TMS reference): 1H δ (ppm) = 
1.296 (t, 3H, CH3), 1.447 (s, 9H, C(CH3)3), 4.221 (q, 2H, CH2CH3), 4.903 (t, 2H, 
CH2NH); 13C δ (ppm) = 14.068, 28.345, 39.439, 41.477, 51.949, 61.701, 64.670, 79.602, 
138.649, 139.339, 140.948, 140.989, 141.836, 141.892, 142.180, 142.927, 143.016, 
143.071, 143.842, 143.881, 144.571, 144.630, 144.646, 144.674, 144.892, 144.919, 
145.036, 145.111, 145.170, 145.193, 145.256, 145.168, 163.535, 166.439, 166.549. The 
mass spectrometry, IR and NMR spectral data are all respectively provided in Appendix 
Figures A2.2, A3.2 and A4.2.
2.3.2.3 Bis(2-acetoxy-1-acetoxymethylethylcarbamoyl)methane (3)
2-amino-1,3-propanediol (25.0 g, 269 mmol) and diethyl malonate (17.5 mL, 112 
mmol) were combined neat and heated with vigorous stirring at 100 °C under argon for 
48 hrs.  The resulting mixture was dissolved in boiling isopropyl alcohol and allowed to 
cool slowly, giving small needles of white, unprotected serinol malonate.  After 
recrystallization was performed twice in isopropyl alcohol, the white solid (Tm: 132 °C) 
was obtained.  The compound is highly soluble in water, DMF, N-Methyl-2-pyrrolidone 
(NMP), methoxyethanol and poorly soluble in alcohols.  
Serinol malonate (25.0 g, 99.9 mmol) was dried under lyophilization, and then 
suspended in pyridine (100 mL, 1240 mmol) at 0 °C, to which acetic anhydride (150 mL,
1590 mmol) was added dropwise over the course of an hour. After reaching 25 °C, 
dissolution occurred and the solution was stirred continuously for 48 hours.  At 0 °C, 
methanol (50 mL, 1225 mmol) was added to quench remaining acetic anhydride and the 
22
solution was stirred for 1 hour, whereupon the solvents were removed in vacuo and the 
residue (yellow oil) was dissolved in isopropyl ether and recrystallized over 48 hours in 
hexane (hexane:isopropyl ether 9:1).  The precipitate was collected by  filtration, washed 
with hexanes and dried in vacuo. Yield: 33 g (79 mmol, 79%). Tm: 91.5–92.5 °C. MS 
Autoflex MALDI-TOF (positive-ion mode): calculated mass = 418.16 Da; observed 
masses = 420.006 Da [M+H+], 450.230 Da [M+Na+]. NMR (500 MHz, CDCl3, 0.05% (v/
v) TMS reference): 1H δ (ppm) = 2.082 (s, 12H, CH3), 3.255 (s, 2H, CH2), 4.181 (d, 8H, 
CH2), 4.405 (octet, 2H, CH), 7.889 (d, 2H, NH); 13C δ (ppm) = 20.129 (4C, CH3), 41.966 
(1C, CH2), 46.855 (2C, CH), 62.002 (4C, CH2), 166.987 (2C, C1⁄4O, amide), 170.159 
(4C, C1⁄4O, ester). The mass spectrometry, IR and NMR spectral data are all respectively 
provided in Appendix Figures A2.3, A3.3 and A4.3.
2.3.2.4 3’-ethoxycarbonyl -3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)- 3'', 
3 ' ' , 3 ' ' ' , 3 ' ' ' , 3 ' ' ' ' , 3 ' ' ' ' , 3 ' ' ' ' ' , 3 ' ' ' ' ' , 3 ' ' ' ' ' ' , 3 ' ' ' ' ' ' -deca- (2 -ace toxy-1 -
acetoxymethylethylcarbamoyl)-3'H, 3''H, 3'' 'H, 3'' ' 'H, 3'' ' ' 'H, 3'' ' ' ' 'H-
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (4)
At 25 °C, 2 (99.5 mg, 0.100 mmol) was dissolved in a solution of 300 mL of 
freshly distilled toluene:CH2Cl2 (2:1), with CBr4 (332 mg, 0.991 mmol) and 3 (837 mg, 2 
mmol) to which a solution of tert-butylimino-tris(dimethylamino)phosphorane (141 mg, 
0.584 mmol) in dry methylene chloride (100 mL) was added over 6 hours.  After 18 
hours, at 25 °C, the product was isolated using flash chromatography 
(chloroform:ethanol, 19:1). Yield: 107.8 mg (35.0 mmol, 35.0%). MS Autoflex MALDI-
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TOF (positive-ion mode): calculated mass = 3073.84 Da; observed masses = 3074.8 Da 
[M+H+], 3097.5 Da [M+Na+], 3113.4 Da [M+K+]. The mass spectrometry and IR spectral 
data are respectively provided in Appendix Figures A2.4 and A3.4.
2.3.2.5 3’-ethoxycarbonyl-3’-((2-ammoniumethoxy)carbonyl)- 3'', 3'', 3''', 3''', 3'''', 
3 ' ' ' ' ,   3 ' ' ' ' ' ,   3 ' ' ' ' ' ,   3 ' ' ' ' ' ' ,   3 ' ' ' ' ' ' - d e c a - ( 2 - h y d r o x y - 1 -
(hydroxymethyl)ethylcarbamoyl)-3'H, 3''H, 3'''H, 3''''H, 3'''''H, 3''''''H-
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene 
monohydrochloride (5)
Product 4 (154 mg, 50.1 mmol) was dissolved in 10 mL of 1,4-dioxane:water 
(99:1) and saturated with HCl gas at 25 °C up  to 1 M concentration.  The reaction flask 
was kept closed for 48 hours at 25 °C, to which solvents were removed in vacuo and the 
product was purified using a cellulose ester dialysis membrane (Thermo Scientific, 2000 
MWCO) over 7 days using DI water, with trace amounts of HCl, to remove acetate and 
isopropyl alcohol.  Yield: 111 mg (49.6 mmol, 99%). MS MicroTOF ESI (positive-ion 
mode): calculated mass = 2134.58 Da; observed masses = 2135.5 Da [M+H+], 2177.5 Da 
[M+Na+]. The mass spectrometry  and IR spectral data are respectively  provided in 
Appendix Figures A2.5 and A3.5.
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2.3.2.6 Paclitaxel-2′-Succinate (6)
Paclitaxel-2′-succinate was prepared by  a modified literature procedure.81 
Paclitaxel (1.00 g, 1.15 mmol) and succinic anhydride (1.80 g, 17.81 mmol) were 
combined and dissolved in dry pyridine (24 mL, 296.4 mmol). The solution was stirred 
under argon at 25 °C for 3 h and then concentrated in vacuo. The residue was treated with 
DI H2O (40 mL), stirred for 20 min, and filtered. The precipitate was dissolved to 
saturation in acetone, after which water was slowly added dropwise to precipitate white 
crystals of 6. The product was then filtered and lyophilized.  Yield: 1.03 g (1.08 mmol, 
93.8%). MS Autoflex MALDI-TOF (positive-ion mode): calculated mass = 953.35 Da; 
observed masses = 954.471 Da [M+H+], 976.466 Da [M+Na+], 992.495 Da [M+K+]. 
NMR (500 MHz, CDCl3, 0.05% (v/v) TMS reference): 1H δ (ppm) = 1.125 (s, 3H), 1.216 
(s, 3H), 1.666 (s, 3H), 1.856 (dd, 1H), 1.908 (s, 3H), 2.200 (s, 4H), 2.329-2.672 (m, 3H), 
2.430 (s, 3H), 3.798 (d, 1H), 4.241 (dd, 2H), 4.426 (ddd, 1H), 4.965 (dd, 1H), 5.504 (d, 
1H), 5.685 (d, 1H), 5.985 (dd, 1H), 6.244 (q, 1H), 6.288 (s, 1H), 7.196 (d, 1H), 
7.309-7.831 (m, 14H), 8.125 (dd, 1H). 13C δ (ppm) = 8.611, 14.766, 20.825, 22.126, 
22.644, 26.771, 28.561, 28.703, 35.510, 35.538, 43.146, 45.572, 52. 774, 58.415, 71.854, 
72.072, 74.159, 75.095, 75.606, 76.415, 78.893, 81.016, 84.438, 126.597, 127.205, 
128.524, 128.690, 128.743, 129.081, 129.181, 130.216, 132.076, 132.794, 133.439, 
133.682, 136.719, 142.608, 166.831, 167.735, 167.932, 169.831, 171.189, 
171.270,175.697, 203.780. The mass spectrometry, IR and NMR spectral data are all 
respectively provided in Appendix Figures A2.6, A3.6 and A4.5.
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2.3.2.7 Serinol-C60-Paclitaxel-2’-Succinate Derivative (7)
Compound 6 (9.54 mg, 0.010 mmol) was dissolved in DMF (200 µL), to which 
triethylamine (2.3 mg, 0.023 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC, 2.11 mg, 0.011 mmol) and 1-hydroxybenzotriazole hydrate (0.5 mg, 
~0.004 mmol, catalytic amount) were added.  Over 5 minutes, to the solution was added 
5 (32.6 mg, 0.015 mmol) in DMF (300 µL), while stirring. The reaction was allowed to 
run for 24 hours, after which the solvent was removed and the water-soluble fraction was 
collected for further purification. The product was isolated using a cellulose ester dialysis 
membrane (Thermo Scientific, 2000 MWCO) for 7 days using DI water to remove water 
soluble byproducts, in the dark to prevent fullerene oxidation. Sample was dried in vacuo. 
Yield: 2.75 mg (0.9 µmol). MS MicroTOF ESI-TOF (positive-ion mode): calculated mass 
= 3071.9 Da; observed masses = 3071.6 Da [M+]. The mass spectrometry  and IR spectral 
data are respectively provided in Appendix Figures A2.7 and A3.7.
Unfortunately, the coupling of paclitaxel-2’-succinate to the fullerene derivative 
was plagued with a poor yield and extreme difficulty in preparative separation of 
compound 7 from compound 5, although HPLC was used to analytically  determine a 
ratio of (Compound 7):(Compound 5). For these reasons, it was decided to take a 
complimentary  synthetic approach to paclitaxel coupling with the hopes of increasing 
both yield and purity of the final conjugate. By utilizing conjugation of paclitaxel to 
polyethylene glycol (PEG), although the yield of the initial synthesis step was less, taking 
advantage of this water-soluble paclitaxel derivative whose synthesis is well-documented 
also produced a higher fullerene-paclitaxel conjugate yield (Compound 9) that was easily 
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purified by HPLC. This higher-yield conjugate permitted synthesis of a fullerene-
paclitaxel conjugate (Compound 9) in sufficient quantity (>100 mg) to conduct the 
animal studies described below.
In vitro studies of compound 7 were performed using A375m melanoma cells, by 
Mr. John W. Marks, in the laboratory of Dr. Michael Rosenblum, Ph.D., at  The University 
of Texas M.D. Anderson Cancer Center (MDACC). However, as we progress to 
performing in vivo studies, we transitioned to the laboratory  of Dr. Steven Curley, M.D., a 
laboratory equipped for animal model testing. To better suit his specialty of hepatic 
cancer, in vitro and in vivo work was performed using the hepatocellular carcinoma Hep 
3B cell line.
2.3.2.8 Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (8)
Paclitaxel-2′-Poly(ethylene glycol) ester was prepared by a modified literature 
procedure.82 Poly(ethylene glycol) bis(carboxymethyl) ether (mPEG acid, Avg. Mn: 600 
Da, 540 mg, 0.900 mmol) was dissolved in trichloroethylene (20 mL), and to this solution 
at 0 °C were added N,N′-diisopropylcarbodiimide (DIC, 176 µL, 1.15 mmol), paclitaxel 
(1.00 g, 1.15 mmol) and 4-dimethylaminopyridine (DMAP, 300 mg, 2.43 mmol). The 
resulting solution was allowed to achieve room temperature and left for 16 h. The 
reaction mixture was washed with 0.005 M HCl, dried, and evaporated in vacuo to yield a 
white solid. At 25 °C, the product  was isolated using flash chromatography, 
(chloroform:methanol, 1:1). Yield: 580 mg (64%). MS Autoflex MALDI-TOF (positive-
ion mode): calculated masses = 1277.53, 1321.55, 1365.58, 1409.60, 1453.63, 1497.66, 
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1541.68, 1585.71, 1629.74, 1673.76, 1717.79, 1761.81, 1805.84 Da; observed masses = 
1278.708, 1322.736, 1366.754, 1410.789, 1454.808, 1498.844, 1542.902, 1586.920, 
1630.972, 1675.000, 1719.051, 1764.033, 1808.182 Da [M+H+], 1300.736, 1344.764, 
1388.827, 1432.827, 1476.859, 1520.893, 1564.968, 1608.990, 1653.069, 1697.077, 
1741.202 Da [M+Na+]. NMR (500 MHz, CDCl3, 0.05% (v/v) TMS reference): 1H 
δ (ppm) = 1.109 (d), 1.177 (s), 1.223 (d), 1.643 (s), 1.671 (d), 1.808 (t), 1.931 (d), 2.043 
(dd), 2.213 (d), 2.333 (s), 2.471 (t), 3.489-3.697 (m), 3.721 (dd), 3.746 (s), 4.013 (bs), 
4.162 (dd), 4.262 (t), 4.244(s), 4.262 (t), 4.272-4.333 (m), 4.367 (dd), 4.433 (dd), 4.904 
(d), 4.934 (d), 5.542 (q), 5.596 (s), 5.610 (s), 5.625 (s), 5.954 (d), 6.085 (t), 6.230 (s), 
6.291 (s), 7.155 (t), 7.301-7.556 (m), 7.631 (q), 7.754 (d), 7.903 (d), 8.071 (d), 8.137 (d). 
13C δ (ppm) = 203.818, 172.816, 171.238, 171.184, 170.471, 169.861, 167.255, 166.842, 
142.787, 134.407, 133.712, 132.540, 130.204, 130.138, 129.210, 129.189, 129.014, 
129.001, 128.702, 128.682, 128.627, 128.516., 128.492, 128.454, 128.435, 128. 408, 
128.186, 127.711, 127.631, 127.568, 127.313, 127.285, 84.414, 84.343, 80.677, 79.015, 
78.942, 76.393, 76.372, 75.612, 75.587, 75.070, 73.455, 72.067, 70.878, 70.867, 70.851, 
70.512, 70.466, 70.444, 70.406, 70.391, 70.381, 70.365, 70.344, 70.310, 70.209, 70.143, 
69.940, 69.910, 69.811, 69.792, 69.751, 69.720, 69.669, 69.632, 69.598, 69.559, 69.525, 
69.511, 58.436, 58.409, 45.594, 45.552, 43.141, 43.130, 43.106, 35.536, 26.777, 26.769, 
26.664, 22.642, 22.098, 22.089, 21.844, 20.873, 20.834, 14.808, 14.690, 9.585, 9.544. 
The mass spectrometry, IR and NMR spectral data are all respectively  provided in 
Appendix Figures S2.8, S3.8 and S4.6.
2.3.2.9 Serinol-C60-Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (9)
Compound 8 (78.97 mg, 0.055 mmol) was dissolved in water (15 mL, 1% MES 
Buffer, pH: 6.75) to which 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC, 8.71 mg, 0.055 mmol) and 1-hydroxybenzotriazole hydrate (HOBt, 
0.5 mg, 0.004 mmol, catalytic amount) were added.  To the solution was added 5 
(108.57 mg, 0.050 mmol) in H2O (10 mL) while stirring. The reaction was allowed to run 
for 6 hours, after which the solvent was removed in vacuo and the product was isolated 
via HPLC. Yield: 5.5 mg (0.020 mmol, 40%). MicroTOF ESI (positive-ion mode): 
calculated masses = 3437.11, 3481.14, 3525.17, 3569.19, 3613.22 Da; observed mass = 
3440.0, 3483.4, 3528.1, 3572.1 Da [M+], 3461.6, 3505.5, 3550.3 Da [M+Na+], 3566.9 Da 
[M+K+]. The mass spectrometry and IR spectral data are respectively  provided in 
Appendix Figures S2.9 and S3.9.
2.3.2.10 3’, 3’’, 3’’, 3’’’, 3’’’, 3’’’’, 3’’’’, 3’’’’’, 3’’’’’, 3’’’’’’, 3’’’’’’-dodeca-(2-hydroxy-1-
{hydroxymethyl}ethylcarbamoyl)-3’H, 3’’H, 3’’’H, 3’’’’H, 3’’’’’H, 3’’’’’’ H-
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (10)
Serinol malonate fullerene was prepared by a modified literature procedure as 
shown in Scheme 5.7  At 25 °C, C60 (1.00 g, 1.37 mmol), CBr4 (4.14 g, 12.36 mmol) and 
3 (5.17 g, 12.36 mmol) were combined and dissolved in 500 mL of a mixture of freshly 
distilled solvent (toluene:CH2Cl2, 1:1). To the resulting solution was added 1.92 g of 
DBU (12.36 mmol). After 18 hours, at 25 °C, the fullerene was isolated using flash 
chromatography, chloroform:methanol mixture (3:1). For removal of the acetate 
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protecting groups, the fullerene was dissolved in MeOH saturated with K2CO3 and 
sonicated for 1 hour, whereupon the solvent was removed in vacuo and the resulting 
product was purified using a cellulose ester dialysis membrane (Thermo Scientific, 2000 
MWCO) for 7 days using DI water. Yield: 819.7 mg (0.371 mmol, 27%). MicroTOF ESI 
(positive-ion mode): calculated masses = 1960.50 (pentakis), 2208.61 Da (hexakis); 
observed mass = 1984.2 (pentakis), 2232.3 (hexakis) Da [M+Na+]. The mass 
spectrometry  and IR spectral data are respectively provided in Appendix Figures S2.10 
and S3.10.
Figure 2.5: Synthesis scheme of 3’, 3’’, 3’’, 3’’’, 3’’’, 3’’’’, 3’’’’, 3’’’’’, 3’’’’’, 3’’’’’’, 3’’’’’’-
dodeca-(2-hydroxy-1-{hydroxymethyl}ethylcarbamoyl)-3’H, 3’’H, 3’’’H, 3’’’’H, 3’’’’’H, 
3’’’’’’ H-hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (10).
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2.3.3 Dynamic Light Scattering Measurements
To understand the behavior of the serinol-C60-paclitaxel-2′-poly(ethylene glycol) 
ester derivative (9) in solution, dynamic light scattering (DLS) measurements were 
performed on a solution of 9 at 100 µg/mL, using a Malvern Zetasizer, Model Zen 3600 
(He-Ne laser, 4.0mW, 632.8 nm; Malvern Instruments Ltd, Malvern, Worcestershire, 
United Kingdom). For comparative purposes, measurements of the unconjugated water-
soluble fullerene derivative (5) and the water-soluble paclitaxel-2′-poly(ethylene glycol) 
ester derivative (8) were measured at equivalent molar concentrations (61.1 µg/mL and 
40.4 µg/mL, respectively). Scans for each solution were performed in triplicate, and for 
better dispersion in solution, all three samples were filtered upon dissolution using a 
Whatman PuradiscTM 25 mm, 0.45 µm pore size, polyethersulfone syringe filter 
(Maidstone, Kent, United Kingdom). Results were graphed using SigmaPlot 9.0 (Systat 
Software, San Jose, California). 
2.4 In Vitro Studies of Gd@C60(OH)x and C60-Paclitaxel Derivatives
2.4.1 In Vitro Cytotoxicity of Serinol-C60-Paclitaxel-2’-Succinate Derivative 
(Compound 7) and Serinol-C60-Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative 
(Compound 9)
A375m melanoma, Hep 3B hepatic carcinoma cells were passed and diluted to 
25,000 cells/mL in medium (DMEM/High Glucose [Life Technologies] with 10% fetal 
bovine serum, non-essential amino acids (1×), MEM  vitamin solution (1×) and sodium 
pyruvate (1×)). The samples were pipetted onto 96-well flat-bottom sterile plates (100 
31
µL/well), with one row left empty for blanks.  For a negative control, T-24 cells were 
passed and diluted to 20,000 cells/mL in medium, then pipetted as above. The plates were 
subsequently  incubated overnight (37 °C, 5% CO2, 100% humidity). Samples of 
paclitaxel, compound 7, PEG-Paclitaxel (compound 8), compound 9 and compound 10 
were then prepared in medium at 2× intended concentration and then pipetted onto the 
cell plates (100 µL/well).  Over the course of the experiment’s 72 hours, when each well 
reached its assigned time point  (4, 8, 24 or 72 hrs.), all media was removed from the well 
and replaced with fresh medium for the remainder of the experiment. After 72 hours, 
medium was removed from each well, and the plates were washed twice with phosphate-
buffered saline, to which crystal violet stain solution was added (100 µL/well) to stain the 
samples for 30 minutes. The stain was removed and the plates were thoroughly washed 
with water and allowed to air-dry. For a more accurate reading, Sorenson’s Buffer (150 
µL/well, 50% ethanol in 0.1 M Citrate (Na+), pH=4.2) was used to solubilize the crystal 
violet stain and the plates were gently shaken for 1 hour. Plates were read at 595 nm on a 
Bio-Tek ELx300 spectrophotometric plate reader, and the results are plotted as the 
log(sample concentration) × percent control [A(595) sample/A(595) no-sample control x 
100]. GraphPad software was used to determine the IC50 points for each sample by non-
linear regression.
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2.4.2 In Vitro Studies of Metallofullerene Immunoconjugates
2.4.2.1 Gd@C60 Immunoconjugate Preparation
Immunoconjugates of Gd@C60(OH)x (hereafter referred to as Gd@C60) were 
prepared using a procedure similar to previous C60-based immunoconjugates, where 
conjugation is achieved via supramolecular chemistry rather than by  conventional 
covalent attachment.83 Gd@C60 was combined in PBS solution with ZME-018 antibody 
(5:1 Gd@C60:ZME-018) and stirred overnight at 4 °C. The solution was then removed 
and purified on a G-25 sephadex size-exclusion column, which removed any non-
conjugated C60 from the sample, using buffer solution (10 mM Na3PO4, 140 mM  NaCl at 
pH=7.2). After Gd@C60-mAb conjugation and purification, Bio-Rad protein assays were 
used to determine concentrations of the antibody in the samples.
2.4.2.2 ELISA Testing of the Gd@C60-mAb Immunoconjugates
The cell binding affinity of the Gd@C60-mAb immunoconjugates was evaluated 
by calculating IP(50) values from enzyme-linked immunosorbent assay (ELISA) plots. 
96-well plates containing adherent A375m (antigen-positive) cell plates were utilized. 
However, to better understand and characterize binding efficiencies and non-specific 
binding, T24 (antigen-negative) cells were also used for comparison with antigen positive 
cells. ELISA plates were prepared by versene-stripping desired A375m cells from tissue 
culture flasks, washing twice using DPBS, before resuspension in DPBS to a cell 
concentration of 1 M/mL. 50 µL of the cell suspension were placed into Falcon 3912 96-
well µL plates, leaving 2 wells without cells for blanks. The plates were dried overnight 
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(37 °C), leaving the cell surface proteins intact, and stored (4 °C). At 25 °C, blocking 
buffer (200 µL) was added to the wells for 1 hour. The blocking buffer was removed via 
decanting, with immediate addition of control standards and experimental solutions (100 
µL/well). The plate was incubated (25 °C) for 3 hours and the solution was removed. 
Each well was washed 3× with a washing buffer for preparation of IgG component 
detection. Anti-mouse IgG-HRP was diluted 1:1000 in diluting buffer, making 11 mL/
plate, which was aliquoted (100 µL/well) and incubated 15 minutes at 25 °C. The wells 
were then washed 3× with washing buffer. H2O2 (11 µL) was added to 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid (ABTS, 11 mL), aliquoted (100 µL/well) and 
incubated for 10 minutes (25 °C). The plate was then read at 405 nm to calculate the 50% 
inflection point of the concentration curve IC50 values.
2.4.2.3 Gd@C60-ZME-018 Immunoconjugate Internalization into A375m Melanoma 
Cells
Cell internalization studies for the Gd@C60-immunoconjugates were performed to 
determine the efficiency and rate with which the cell-specific Gd@C60-
immunoconjugates internalize into melanoma cells.  Antigen positive (A375m) and 
negative (T24) cells were prepared on 100 mm2 tissue culture plates at 2×106 cells/plate 
in Dulbecco's modified eagle medium (10% fetal bovine serum, pH=7.4).  The cells were 
incubated overnight at 37 °C, followed by addition of 1×10-6 g/mL (6.67 nM), 10 mL/
plate, of the Gd@C60-immunoconjugates over various time frames. The plates were 
incubated for 1, 2, 4 and 24 hours at 37 °C. At the end of the incubation period, the media 
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was removed and each cell sample washed with glycine buffer solution (10 mL, 0.05 M, 
pH 2.5 + 0.1 M NaCl), to remove any remaining cell-surface bound Gd@C60-
immunoconjugate. The sample plates were then washed with a neutralizing buffer (0.15 
M Tris, pH 7.4), 10 mL. Using a trypsin solution (0.25% Trypsin + EDTA [GIBCO]), the 
cells were then detached and centrifuged for ICP-MS analysis.  Trypsinization has not 
been previously shown to be a factor in influencing the outcome of internalization 
studies.
2.4.2.4 Determination of Gd3+-ion concentration for the Gd@C60-(ZME-018) 
Immunoconjugates in A375m Melanoma Cells
Once the binding efficiency had been determined to have been retained for the 
immunoconjugates, samples of the conjugates (0.667 nM) were digested with oxidizing 
HNO3 (70%), heated to dryness and ICP-MS spectrometry  was then used to determine the 
conjugate Gd@C60:mAb ratio. For each cell internalization study, ICP-MS sampled and 
measured the [Gd3+] ten times for each of the Gd@C60-(ZME-018) and Gd@C60-
(MuIgG) immunoconjugates.  An average of ten determinations per time point was used 
as the final [Gd3+] with its standard deviation.  ICP-OES to determine the Gd3+ 
concentration of the Gd@C60(OH)x/C60(OH)x sample was performed using a Perkin-
Elmer Optima 3000 DV ICP-OES system.  ICP-MS to determine the Gd3+ concentration 
of the Gd@C60-(ZME-018), Gd@C60-(MuIgG), A375m and T24 samples were performed 
using a Varian 810 quadruple ICP-MS system.
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2.4.3 In Vitro Studies of C60-Paclitaxel Immunoconjugates
2.4.3.1 Serinol-C60-Paclitaxel-2’-Succinate Derivative Immunoconjugate 
Preparation
Immunoconjugates of serinol-C60-paclitaxel-2’-succinate immunoconjugate were 
prepared using the procedure stated in 2.4.2.1, combining compound 7 separately with 
ZME-018 and MuIgG2a mAb samples (5:1) and stirring overnight at 4 °C.  The sample 
solutions were then removed and purified on a G-25 sephadex size-exclusion column, 
which removed any non-conjugated 7 from the sample, using buffer solution (10 mM 
Na3PO4, 140 mM  NaCl at pH=7.2). After 7-mAb conjugation and purification, Bio-Rad 
protein assays were used to determine concentrations of the antibody in the samples. 
Additionally, for determination of the final 7:mAb ratio, the UV-Vis spectra of the naked 
antibodies and their compound 7-immunoconjugates were obtained. 
2.4.3.2 In Vitro Timed Pulse Experiment for the Serinol-C60-Paclitaxel-2’-Succinate 
Derivative Immunoconjugates
In vitro cytotoxicity of the Serinol-C60-Paclitaxel-2’-Succinate Derivative 
Immunoconjugates was determined using the same procedure listed in 2.4.1, utilizing 
A375m melanoma and T-24 bladder carinoma (control) cells. 
2.5 In Vivo Studies of a C60-Paclitaxel Derivative (Compound 9)
The animal experiments were performed by Mr. Brandon H. Cisneros at the M.D. 
Anderson Cancer Center. Cells from a luciferase, green fluorescent protein-transfected, 
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Hep 3B cell line were injected underneath the liver capsule of 29 severe combined 
immunodeficiency  (CB17-SCID) mice, giving them orthotopic, hepatocellular 
carcinomas. Cells for this injection were cultured per American Type Culture Collection 
(ATCC) recommendations for Hep 3B cells. Four weeks post-injection, tumor growth in 
the mice was assessed using in vivo luminescence imaging by injecting the mice with 
luciferin (25 mg/kg, single dose). Luminescence was observed in all mice, indicating 
conversion of luciferin to oxy-luciferin with generation of light. This confirmed the 
presence of carcinomas.  The mice were then randomized into five equal groups of six 
mice determining the material administered to them: (1) paclitaxel (suspended in 
Cremophor EL), (2) Abraxane® (a water soluble, clinically-available form of paclitaxel 
bonded to albumin), (3) compound 9 (C60-paclitaxel), (4) compound 10 (water soluble 
C60-serinol), and (5) phosphate buffered saline (PBS, control).  The group administered 
10 consisted of five mice instead of six.
For the paclitaxel group, paclitaxel was administered per intraperitoneal (IP) 
injection for 5 consecutive days at 12.5 mg/kg per dose per mouse in 100 µL sterile 1× 
PBS dilution. Abraxane and 9 were administered, each to their respective groups, for 5 
consecutive days per IP injection, at 30 mg paclitaxel (equivalent)/kg per dose per mouse, 
in 100 µL sterile 1× PBS dilution. Concentrations for 9 were calculated with the 
assumption that the sample was 90% pure. Compound 10 was administered at  78 mg/kg 
per dose per mouse, in 100 µL sterile 1× PBS dilution. This dosage of water-soluble, non-
conjugated fullerene represents the molar equivalent to that of 9 administered to the mice 
in their group. Prior to injection, each of the mice was weighed.  
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Hydrolysis of the ester linkage formed with paclitaxel’s 2’ hydroxyl appeared to 
be relatively labile and would precipitate in aqueous solutions over time, so careful steps 
were necessary to preserve its integrity. Dilutions of Abraxane and paclitaxel were 
prepared freshly each day of administration, while solutions of 9 were prepared in 
advance and frozen to prevent degradation. Aliquots of 9 were thawed per necessity and 
administered within an hour.
According to protocol, the study was to be terminated when two mice in any 
single treatment group (other than controls) required euthanasia. This was required to 
preserve statistical power for inferential testing while allowing maximum time for 
treatment effect. This occurred first in the control group, with mice being euthanized on 
days 5 and 7, and then subsequently in the Abraxane group, on day 9. Primary 
euthanization of the mice was performed with CO2 and secondary euthanization was with 
cervical decapitation. Samples of kidney, liver, and intestine were fixed in formalin, while 
tumors were excised, trimmed of any healthy or adherent tissues, weighed and then 
divided. One portion of the tumor sample was flash frozen to allow for possible future 
paclitaxel quantification, and the remainder was fixed in formalin. Results were graphed 
using KaleidaGraph 4.1 (Synergy Software, Reading, Pennsylvania) and statistical data 
was obtained utilizing GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, 
California).
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Chapter 3
Results
3.1 Dynamic Light Scattering Characterization
Aggregation measurements of the hydrodynamic diameter (Dh) of compounds is 
comparable to previous results with fullerenes and of the same order of magnitude.20,84,85 
Results obtained by Zakharian et al. for hydrophobic C60-paclitaxel liposomes show that 
Dh≈130 nm, independent of suspension concentration, while Laus et al. demonstrate 
larger Dh values for extremely hydrophilic endohedral fullerene derivatives (Dh=810.7 
nm for Gd@C60(OH)x, Dh=720.6 nm for Gd@C60[C(COOH)2]10). The aggregation results 
for the water-soluble compound 9 are evident, in that although chemically  similar in 
nature to hydrophobic C60-paclitaxel, the water-solubilizing groups attached not only 
increase its hydrophilicity, but also its mass and volume. Thus measured aggregate sizes 
increase as the water-solubilizing groups attached allow the serinol-C60-paclitaxel-2′-
poly(ethylene glycol) ester derivative to more closely  approximate the hydrophilic nature 
of C60(OH)x.
In measuring the unconjugated fullerene, compound 5, a small measurement at 
~5000 nm was found in only  one of the three scans and is an H2O artifact that 
inconsistently  appears periodically. Additionally, the distribution in measured sizes of 
compound 9 shows a slight tail, with a minor aggregate size of about 10% the intensity of 
the main size, centered around Dh=78.82 nm. This distribution, however, is not 
considered bimodal and demonstrates that the sample is completely aggregated in 
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solution. Mean intensities of the measured hydrodynamic diameters are provided in 
Appendix A5.
Figure 3.1.1: DLS Histogram of particle aggregation size in aqueous solution of water-
soluble unconjugated serinol-C60 (5, 61.1 µg/mL). Error bars represent +/- one standard 
deviation. 
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Figure 3.1.2: DLS Histogram of particle aggregation size in aqueous solution of 
paclitaxel-2′-poly(ethylene glycol) ester derivative (8, 40.4 µg/mL). Error bars represent 
+/- one standard deviation.
Notes: 25°C; 4.65 mm position; attenuator at 11; 15 measurements per run; 0.1 mg/mL Conjugated C60 
and respective concentrations of uncongated C60 and Taxol-Peg; all solutions were syringe filtered using 
a 0.45 µm PES filter. 
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Figure 3.1.3: DLS Histogram of particle aggregation size in aqueous solution of serinol-
C60-paclitaxel-2′-poly(ethylene glycol) ester derivative (9, 100 µg/mL). Error bars 
represent +/- one standard deviation.
Compound 5 Compound 8 Compound 9
Concentration (μg/mL)
Average Hydrodynamic 
Diameter (Dh, nm)
61.1 40.4 100
294.2 247.6 244.5
Table 3.1.1: Average hydrodynamic diameter sizes for molar equivalent concentration 
solutions of serinol-C60-paclitaxel-2′-poly(ethylene glycol) ester derivative (compound 9) 
and its synthetic precursors (compounds 5 and 8).
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3.2 In Vitro Studies of Gd@C60(OH)x and C60-Paclitaxel Derivatives
3.2.1 In Vitro Cytotoxicity of Serinol-C60-Paclitaxel-2’-Succinate Derivative 
(Compound 7) and Serinol-C60-Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative 
(Compound 9)
 Cytotoxicity results of the studies performed on oncology cell lines revealed a 
puzzling contrast (Figure 3.2.1). Primarily, it was confirmed that when quantifiable, 
measurements of cytotoxicity within the first 4 and 8 hour time points were negligible. 
Additionally, an IC50 value for the control water-soluble fullerene compound 10 was 
negligible due to no observable cytotoxic activity. Secondly, paclitaxel showed consistent 
cytotoxicity across all three cell lines. However, compound 7 and PEG-Paclitaxel 
(compound 8) demonstrate, that once the paclitaxel is conjugated, its cytotoxicity 
markedly decreases and its IC50 increases. Finally, compound 9 showed the surprising 
result that once paclitaxel is conjugated to a water-soluble fullerene via a 2’-
poly(ethylene glycol) ester bond, its efficacy increases significantly over paclitaxel itself.
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Figure 3.2.1: In Vitro Timed Pulse Cytotoxicity  assay  of paclitaxel, compound 7, 
compound 9, Abraxane and PEG-paclitaxel in A375m, T-24 and Hep 3B cancer cell lines. 
Almost all measurements for the 4 and 8 hour timepoints, as well as those for the 
compound 10 control provided R2 values less than 0.80, indicating limited toxicity, and 
were thus excluded from the figure. Where indicated, error bars represent +/- one 
standard deviation.
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3.2.2 In Vitro Studies of Metallofullerene Immunoconjugates
3.2.2.1 ELISA Testing of the Gd@C60-mAb Immunoconjugates
To determine whether specific binding was retained upon fullerene conjugation, 
the ELISA binding curves and IP(50) values, which reflect binding efficiencies, were 
determined for both the Gd@C60–(ZME-018) and Gd@C60-(MuIgG) immunoconjugates 
in both A375m and T-24 cell lines (Figure 3.2.2). IP(50) values in the A375m cell line, 
for the Gd@C60–(ZME-018) immunoconjugate (IP(50)=44.8 ng/mL) and non-conjugated 
ZME-018 (IP(50)=43.9 ng/mL) were practically identical, reflecting unchanged specific 
targeting of the antibody upon conjugation. Comparing the targeting of Gd@C60–
(ZME-018) to the negative nonspecific Gd@C60-(MuIgG) immunoconjugate 
(IP(50)=1228 ng/mL) to A375m cells, the binding was nearly 800 times more efficient, 
indicating that Gd@C60–(ZME-018) clearly retains cell specificity  over a non-targeting 
mAb. Finally, to measure any increase in nonspecific immunoconjugate binding, the 
IP(50) value of Gd@C60–(ZME-018) was determined for T24 (human bladder 
carcinoma) cells. At IP(50)=13,320 ng/mL, this represents a measurable increase in 
nonspecific binding over the unmeasurable IP(50) value of unconjugated ZME-018 mAb. 
However, the difference between specific and nonspecific binding is still greater by a 
factor of almost 300. The results shown here indicate little change in the specific binding 
of the Gd@C60-(ZME-018) immunoconjugate from the original, unconjugated ZME-018 
antibody.
Figure 3.2.2: ELISA (Dry-cell) A375m (+) and T-24 (-): Two hour incubation, dead cell 
tests of the Gd@C60-immunoconjugates
3.2.2.2 Determination of Gd3+-ion concentration for the Gd@C60-(ZME-018) 
Immunoconjugates in A375m Melanoma Cells
ICP-MS determined the [Gd3+] of each fullerene immunoconjugate sample, 
whereupon the total fullerene concentration (assuming only 41.9% of the sample is 
Gd@C60(OH)x) in the sample and the total fullerene (Gd@C60(OH)x+C60(OH)x):mAb 
ratio were calculated (Tables 3.2.1 and 3.2.2). The results showed a relatively  close 
adherence to the 5:1 ratio in which the fullerene and mAb were combined, though 
measured drops in the ratio could be due to fullerene lost over the course of the 
experiment, possible through separation on the Sephadex column.
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mAb 
Conjugate
mAb 
Concentration 
(nM)1
Gd@C60 
Concentration 
(nM)
Total Fullerene 
(Gd@C60+C60) 
Concentration (nM)2
Total 
Fullerene:mAb 
Ratio
Gd@C60-
(ZME-018) 0.667 1.42 3.39 5.09
Gd@C60-
(MuIgG) 0.667 1.39 3.30 4.96
Table 3.2.1: ICP-MS results for the Gd@C60(OH)x immunoconjugates and the calculated 
Gd@C60+C60:mAb ratio for Experiment 1.
mAb 
Conjugate
mAb 
Concentration 
(nM)1
Gd@C60 
Concentration 
(nM)
Total Fullerene 
(Gd@C60+C60) 
Concentration (nM)2
Total 
Fullerene:mAb 
Ratio
Gd@C60-
(ZME-018) 0.667 1.34 3.19 4.78
Gd@C60-
(MuIgG) 0.667 1.35 3.23 4.85
Table 3.2.2: ICP-MS results for the Gd@C60(OH)x immunoconjugates and the calculated 
Gd@C60+C60:mAb ratio for Experiment 2.
1)  Determined by BioRad protein assay.
2) Determined assuming the composition of metallofullerene in the mAb sample contained 41.9% 
Gd@C60(OH)x and 58.1% C60(OH)x.
For the time-dependent cell internalization experiments, the Gd3+-ion 
concentration for both the Gd@C60-(ZME-018) and Gd@C60-(MuIgG) samples were 
each determined ten times using ICP-MS for the experiment run in duplicate (Tables 
A6.1 and A6.2). For Experiment 1, the Gd@C60-(ZME-018) immunoconjugate exhibited 
an increase in delivery of Gd@C60 to the A375m cells, peaking in concentration of 
9.38×1013 Gd@C60+C60 molecules/cell at the two hour time point (Table A6.1) and then 
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slowly declining to an average of 4.75×1013 Gd@C60 molecules/cell after 24 hr (Figure 
3.2.3). Experiment 2 yielded similar results, with the Gd@C60-(ZME-018) 
immunoconjugate peaking in concentration at  9.34×1013 Gd@C60+C60 molecules/cell at 
the two hour time point (Table A6.2) and then slowly declining to an average of 
4.31×1013 Gd@C60 molecules/cell after 24 hr (Figure 3.2.3). Results from both of these 
experiments indicate a significant preferential internalization for the targeting Gd@C60-
(ZME-018) to A375m cells over the non-targeting controls. 
Figure 3.2.3: Internalization of Gd@C60-mAb immunoconjugates into cells over time 
(Experiment 1). Error bars represent one +/- one standard deviation for ten individual 
[Gd3+] determinations for each time point. 
0
5 1012
1 1013
1.5 1013
2 1013
0 5 10 15 20
A375m Gd-OH-(ZME-018) Experiment #1
A375m Gd-OH-(MuIgG) Experiment #1
T24 Gd-OH-(ZME-018) Experiment #1
T24 Gd-OH-(MuIgG) Experiment #1
m
A
bs
 p
er
 C
el
l
Hours of Immunoconjugate Exposure
48
Figure 3.2.4: Internalization of Gd@C60-mAb immunoconjugates into cells over time 
(Experiment 2). Error bars represent one +/- one standard deviation for ten individual 
[Gd3+] determinations for each time point.
3.2.3 In Vitro Studies of C60-Paclitaxel Immunoconjugates
3.2.3.1 Serinol-C60-Paclitaxel-2’-Succinate Derivative Immunoconjugate 
Preparation
To quantitatively  confirm conjugation of compound 7 to both ZME-018 and 
MuIgG, UV-Vis spectra (Figure 3.2.4) of the naked antibodies and their Compound 7-
immunoconjugates were obtained, as well as compound 7. Using Beer’s Law (A=εlc) to 
calculate the additional absorbance produced from the fullerene component of the 
immunoconjugate, the ratios of 7:ZME-018 and 7:MuIgG were determined to be 4.86 and 
5.24 respectively. 
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Figure 3.2.5: UV-Vis spectra comparing the two immunoconjugates to the two naked 
antibodies. The immunoconjugates exhibited increased absorbance from 250-450 nm, 
especially at shorter wavelengths.
3.2.3.2 In Vitro Timed Pulse Experiment for the Serinol-C60-Paclitaxel-2’-Succinate 
Derivative Immunoconjugates
Results from cytotoxicity  studies for compound 7 demonstrated some intriguing 
results. First, as determined in 3.2.1, conjugation of paclitaxel to water-soluble C60 via 
succinic acid decreases the cytotoxicity of paclitaxel. This result, however, is in 
accordance with previous studies.20,82 Second, upon conjugation of compound 7 to the 
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mAb, all visible targeting behavior of the antibody was lost. The Compound 7-
(ZME-018), which targets A375m cells, showed a 50% increase in the IC50 over the non-
targeting MuIgG control immunoconjugate. These results were additionally reflected in 
the control T-24 cells, where the MuIgG immunoconjugate showed greater cytotoxicity 
than the ZME-018. Since neither the ZME-018 or MuIgG antibody targets T-24 cells, no 
measurable difference in cytotoxicity should be demonstrated between the 
immunoconjugates.
Figure 3.2.6: In Vitro Timed Pulse Cytotoxicity assay of paclitaxel, compound 7 and 
immunoconjugates in A375m melanoma and T-24 bladder carcinoma cell lines. Almost 
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all measurements within the 4 and 8 hour timepoints provided R2 values less than 0.90, 
excluding them from the figure. 
3.3 In Vivo Studies of a C60-Paclitaxel Derivative
Throughout the course of in vivo testing, most of the animal masses remained 
relatively unchanged, with both the averages and standard deviations holding steady. 
However, there was a noticeable decline over time, in the body  masses of the Abraxane 
group, a trend which by day  7 triggered the veterinary staff to give gel food to all mice, 
excluding the experimental (compound 9) group, in order to help  them better cope with 
weight loss. Masses of murine subjects during the course of the experiment are provided 
in Appendix A7.
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Figure 3.3.1: Average mass of in vivo murine test subjects during treatment with 
paclitaxel derivatives. Error bars represent +/- one standard deviation. 
Overall, the subject tumor mass results appear to better reflect the treatment 
efficacy than results measured in murine body mass. While the control samples, 
compound 10 and PBS, predictably  show the greatest increase in tumor mass, with one 
PBS subject dying on day 4, and one undergoing euthanization on day 6, due to excessive 
tumor burden. Of the five materials tested, paclitaxel remains the most effective at 
controlling overall tumor growth. Interestingly, the subject group administered compound 
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9, the experimental fullerene sample, showed resulting tumor masses comparable to the 
clinically-approved Abraxane.
To determine whether the in vivo results demonstrate that compound 9 is 
significantly different from PBS control when administered to murine subjects, a two-
tailed t-test was performed, with the null hypothesis being that there is no difference in 
tumor mass between the compound 9 and PBS control groups. Statistical calculations of 
compound 9 versus the PBS control show a P value of 0.0869, indicating a retention of 
the null hypothesis on the 95% confidence level. Interestingly, comparison of FDA-
approved Abraxane with PBS control shows a P value of 0.0840, a value close to 0.0869, 
and one that also fails to demonstrate a difference in treatments on the 95% confidence 
level. The source of these failures most likely stems from the small number of subjects in 
each treatment group, leading to a large standard deviation in the measurements and thus 
difficulty ascertaining whether the observations reflect a truly significant difference 
between the treatment and control groups.
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Figure 3.3.2: Average tumor mass in murine test subjects after treatment with paclitaxel 
derivatives. Error bars represent +/- one standard deviation. 
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Chapter 4
Discussion
Currently, the development of a paclitaxel-C60 conjugate described in this thesis 
serves as a contribution to the growing library of research utilizing fullerenes as therapy 
modalities. However, as the first well-characterized, water-soluble C60 conjugate for 
specific use as a drug delivery vehicle, the potential is great for the development of new 
fullerene conjugates and therapeutic development of FIT.
The synthetic hurdles for compounds 7 and 9 were formidable in achieving the 
final product derivatives.  Although the initial step of synthesizing paclitaxel-2’-succinate 
was facile, its conjugation to 5 was plagued by low yields and difficult to purify, making 
it unsuitable for in vivo testing. By using a well-documented synthesis to conjugate 
poly(ethylene glycol) to paclitaxel, and then covalently  attaching the conjugate to water-
soluble C60, a system has been developed for producing water-soluble fullerene 
derivatives in sufficient quantities for drug delivery. In particular contrast to other 
fullerene-drug conjugates,38,39,40,41 compounds 7 and 9 are uniform and well 
characterized, a requisite for therapies seeking FDA approval for clinical use.
In the development of FIT, conjugating water-soluble paclitaxel-C60 derivatives to 
antibodies reveal the need for further investigation. Our initial studies, utilizing 
Gd@C60(OH)x, determined that C60-mAb immunoconjugates maintain selective binding 
and internalize into A375m melanoma cells, taking Gd@C60(OH)x with them. However, 
when replicating these internalization experiments with compound 7, cytotoxicity was 
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maintained, though there was no demonstrated significant difference between targeted 
A375m and control T-24 bladder carcinoma cells.
In these experiments, the loss of specific delivery of paclitaxel, but maintenance 
of overall cytotoxicity, is attributable to one of two factors. The first possibility is that 
paclitaxel is being prematurely liberated from the fullerene before it  can properly 
internalize into the cell, either via esterase activity  or spontaneous ester hydrolysis. 
Addressing this possibility  requires either a more biostable linker at paclitaxel’s 2’ 
hydroxyl, or conjugating an ester linkage to either the 1- or 7- hydroxyl on paclitaxel. 
 Chemistry provides only  a limited number of biolabile linkers that are strong 
enough for eventual delivery under biological conditions, yet labile enough for eventual 
release, usually  triggered either by a drop in pH (consistent with cancer cells) or 
enzymatic activity. The first candidate for a stronger linker would be an ester linker α-
substituted with aliphatic groups. This approach would maintain similar chemistry to that 
already developed above, but electrostatic induction from electron donating aliphatics 
would serve to strengthen the adjacent ester bond, thus making the paclitaxel less labile. 
Additional approaches include replacing the 2’-ester bond with a carbamate or carbonate 
ester bond for greater stability. These classes of bonds are frequently  used in 
pharmaceutical chemistry due to their simultaneous biostability and lability, but their 
formation and purification can be challenging and would most likely prove difficult  for a 
molecule such as paclitaxel. The additional possibility also exists for utilizing either of 
paclitaxels 1- or 7-hydroxyls. This approach, however, is challenged by both the 
significant steric unreactivity of paclitaxel’s 1-hydroxyl, thus rendering esterification 
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difficult, and the marked decrease in activity of 7-hydroxy esters due to overstability. 
86,87,88
 Another possible explanation for the limited activity demonstrated by compound 
7-mAb immunoconjugates is that while 7 is stable in associating with mAbs in PBS 
solution, introduction into medium disrupts the supramolecular forces holding the 
fullerene to the mAb. If the fullerene conjugate is semi-labile in the presence of other 
proteins, this too would explain the results of the immunoconjugate, where cytotoxicity is 
maintained, yet selective activity for A375m cells is not.
While either premature 2’-ester hydrolysis or antibody-fullerene dissociation is a 
viable possibility, a previous study demonstrated similar results, where paclitaxel-2’-
succinate was conjugated to the anti-epidermal growth factor receptor antibody 
cetuximab (C225) for in vivo treatment of A431 human epithelial carcinomas.89 In the 
study, while the antibody-drug conjugate retained binding and cell internalization 
properties, tumor growth inhibition between the paclitaxel-C225 conjugate and naked 
C225 was not significantly  different. This led the study’s authors to conclude that either 
only a small quantity  of antibody-delivered paclitaxel was being internalized into the 
tumor cells, or that paclitaxel was being prematurely  released from the antibody, before 
targeted delivery to cells.
Future work to determine the reason behind loss of activity in the fullerene 
immunoconjugate can be performed by first covalently attaching the fullerene to the mAb 
for direct delivery and internalization into targeted cells. This strategy is already 
employed for clinical antibody-drug conjugates, and could be taken advantage through 
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the following. By reacting 2-iminothiolane (Traut’s reagent) with an antibody sample, 
each individual antibody is covalently labeled with an average of 5 free thiols. For the 
fullerene, by functionalizing both arms of the linker malonate with protected amines, a 
second group is introduced for controlled fullerene functionalization. Whereby  a 
paclitaxel (or other proposed chemotherapeutic) molecule may be attached to one arm of 
the linker malonate, the amine on the other malonate arm can be combined with the 
reactive linker 3-(2-Pyridyldithio)propionic acid (SPDP), producing a terminal thiol for 
antibody functionalization via disulfide bond. Once covalently attached to the mAb, if 
cytotoxicity of a paclitaxel-C60 derivative maintained the same blanket specificity  for 
both targeted and non-targeted cells, varying the linker used to attach paclitaxel to C60 
would be the next step towards development of FIT.
Given the previous success of using Gd@C60(OH)x-mAb immunoconjugates for 
cell internalization, the most likely cause to describe the lack of cytotoxic specificity  seen 
in the results would be from spontaneous ester hydrolysis, releasing paclitaxel into 
solution before cell internalization. Although paclitaxel itself already contains four ester 
bonds, α-hydroxy acid esters, such as the one used to link paclitaxel to C60, can be 
notoriously  labile in solution, thus contribution to an explanation as to why overall 
cytotoxicity of paclitaxel is preserved, but indiscriminate between the targeted A375m 
and control T-24 cells. 
Due to the synthetic hurdles of compound 7, especially a low production yield, it 
was determined to be necessary to pursue another derivative, compound 9, to achieve the 
end goal of obtaining enough product for in vivo testing. Additionally, compared to 
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paclitaxel and FDA-approved Abraxane, in vitro testing of conjugate 9 yielded excellent 
results, showing 10.1× and 5.29× better cytoxicity than paclitaxel and Abraxane, 
respectively. In vivo testing of compound 9 in a murine model showed tumor volume 
reduction similar to FDA-approved Abraxane, without the associated weight-loss, 
begging further investigation for compound 9 as a therapy  for both antibody-drug 
conjugation and as a stand alone water-soluble form for delivery of hydrophobic 
paclitaxel. 
Future work is still necessary to fulfill the fullerene immunotherapy (FIT) vision 
of a comprehensive fullerene-antibody  conjugate for targeted drug delivery. The work in 
this thesis suggests that Gd@C60(OH)x immunoconjugates do, indeed, internalize into 
target cells, without covalent attachment. However, successive work is based on the 
assumption that water-soluble C60(OH)x and serinol-C60 derivatives behave similarly in 
solution. To better understand the loss of targeting behavior seen in the 
immunoconjugate, the system needs to be better characterized by uncovering the reason 
behind loss of specific delivery to targeted cells. This should first  be accomplished by 
using SPDP or another biochemical moiety to covalently attach compound 9 to the 
targeting vector, preventing loss of the potentially  labile fullerene to surrounding media 
proteins. If subsequent results prove to be similar to those already seen in this work, then 
it is reasonable to assume that  cytotoxicity loss is due to premature release of paclitaxel, 
before it can be delivered and internalized into the targeted cell. To solve this problem, a 
more stable linker will be necessary, such as a substituted ester or a carbamate or 
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carbonate ester linker to create a stronger, biologically-labile covalent bond to affix 
paclitaxel to C60.
Developing linker technology for effective conjugation of drugs to antibodies is 
currently an important area of focus in pharmaceuticals. Acid-labile hydrazones were 
initially championed for their stability in neutral blood plasma and ability to hydrolyze at 
acidic pHs, such as those produced by anaerobic metabolism found in cancer cells. 
However, the 48-72 hour half-life for drug release of hydrazones in vivo does not appear 
to be long enough for optimal therapy, compared to the 6-10 days found for their peptide 
counterparts.90  The use of peptide-based linkers is proving to be a significant advantage 
over traditional hydrolytic or reductively labile linkers, since hydrolysis is enzymatic. 
This allows for individual preferential selection of linkers hydrolyzed by enzymes 
expressed or overexpressed in tumor cells or tumor masses. Using these peptide 
sequences for intracellular drug release, antibody-drug conjugates have been prepared 
using doxorubicin,91 mitomycin C,92 camptothecin,93 talisomycin,94 and auristatin 
derivatives.93,95-97 As these peptide linkers become more specialized and developed for 
specific cancer lines, successful development of fullerene immunotherapy may eventually 
utilize one of these linkers to either anchor chemotherapeutic drugs to a fullerene or a 
fullerene conjugate to a targeting antibody.
Peptide linkers have been used for paclitaxel before. Firestone et al. reported a 
paclitaxel-peptide conjugate for antibody conjugation as early as 1994, using a peptide 
linker analogous to that of FDA-approved brentuximab vedotin.98 Further development to 
conjugate the paclitaxel to an antibody never took place, possibly once it became evident 
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in the interim that for antibody-drug conjugates to be effective in human clinical use, 
drug IC50 values must be at least 10-100 pM, making paclitaxel (IC50≈1-10 nM) possibly 
unsuitable.99  
The main success of this thesis is the progress made toward further development 
of FIT and the potential translation of FIT into the clinic. Using Gd@C60(OH)x, the basic 
premise of using FIT to deliver fullerenes to targeted cells has been realized. The next 
step toward development of a therapeutic fullerene-antibody immunoconjugate is to 
transition from endohedral Gd@C60 to the paclitaxel-C60 conjugate. However, by  using 
the carbon-cage structure of C60 to constructing a water-soluble scaffold to covalently 
functionalize lipophilic paclitaxel, a new biologically-inert modality  has been achieved to 
overcome the usual problem of pharmaceuticals in solubility, a challenge that currently 
limits approximately 40% of therapies from even reaching clinical trials.100 Finally, the 
results documented in this work shifted the onus of FIT from a theoretical concept to a 
realistic goal of applied science awaiting final developmental refinement.
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Chapter 6
Appendix
Appendix A1: Chemicals and their related information used in Section 2.3
Chemical Purity CAS Commercial Source
2-Aminoethanol 99% 141-43-5
Sigma-Aldrich, St. Louis, 
Missouri
Di-tert-butyl pyrocarbonate ((Boc)2O) 99% 24424-99-5
Oakwood Products, Inc., 
West Columbia, South 
Carolina
Ethyl malonyl chloride ≥95% 36239-09-5
Fluka, GmbH, Buchs, 
Switzerland
Ethyldiisopropylamine (DIPEA, 
Hünig’s base) 99% 7087-68-5
Alfa-Æsar, Ward Hill, 
Massachusetts
Ethyl acetate (EtOAc) ≥99.5% 141-78-6
Sigma-Aldrich, St. Louis, 
Missouri
Hexanes, mixture of isomers ≥98.5%
Sigma-Aldrich, St. Louis, 
Missouri
C60 99+% 99685-96-8
MER Corp, Tucson, 
Arizona
Carbon Tetrabromide (CBr4) 99% 558-13-4
Sigma-Aldrich, St. Louis, 
Missouri
1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) 98% 6674-22-2
Sigma-Aldrich, St. Louis, 
Missouri
Toluene ≥99.5% 108-88-3
Sigma-Aldrich, St. Louis, 
Missouri
2-Amino-1,3-propanediol (Serinol) 98% 534-03-2
AK Scientific, Inc., 
Mountain View, California
Diethyl malonate 99% 105-53-3
Sigma-Aldrich, St. Louis, 
Missouri
2-Propanol (Isopropyl alcohol) 99.9% 67-63-0
Fisher, Pittsburgh, 
Pennsylvania
Pyridine 99.9% 110-86-1
Fisher, Pittsburgh, 
Pennsylvania
Acetic anhydride ((Ac)2O) 99.7% 108-24-7
Fisher, Pittsburgh, 
Pennsylvania
Methanol (CH3OH) ≥99.5% 67-56-1
Sigma-Aldrich, St. Louis, 
Missouri
Isopropyl ether 99+% 108-20-3 Acros, Geel, Belgium
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tert-butylimino-
tris(dimethylamino)phosphorane 
(phosphazene base P1-t-Bu)
97+% 81675-81-2 Sigma-Aldrich, St. Louis, 
Missouri
Methylene chloride (CH2Cl2) 99.9% 75-09-2
Fisher, Pittsburgh, 
Pennsylvania
Chloroform (CHCl3) ≥99.8% 67-66-3
Sigma-Aldrich, St. Louis, 
Missouri
Ethanol (CH3CH2OH) 100% 64-17-5
Decon Labs, King of 
Prussia, Pennsylvania
1,4-Dioxane >99% 123-91-1 Mallinckrodt
Deionized water
>18 
MOhm 7732-18-5
Hydrochloric acid, aq. 37% 7647-01-0
EMD Chemicals, Geneva, 
Switzerland
Dimethyl formamide (DMF) ≥99.9% 68-12-2
Sigma-Aldrich, St. Louis, 
Missouri
Paclitaxel 98% 33069-62-4
AK Scientific, Inc., 
Mountain View, California
4-(Dimethylamino)pyridine 99% 1122-58-3
Sigma-Aldrich, St. Louis, 
Missouri
Succinic Anhydride 99% 108-30-5
Alfa-Æsar, Ward Hill, 
Massachusetts
Poly(ethylene glycol) 
bis(carboxymethyl) ether (Avg. Mn: 
600 Da)
39927-08-7 Sigma-Aldrich, St. Louis, 
Missouri
Trichloroethylene ≥99.5% 79-01-6
Sigma-Aldrich, St. Louis, 
Missouri
N,N′-diisopropylcarbodiimide (DIC) ≥99% 693-13-0
Advanced ChemTech, 
Louisville, Kentucky
1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide Hydrochloride 
(EDC)
98% 25952-53-8 TCI America, Portland, 
Oregon
1-Hydroxybenzotriazole hydrate 
(HOBt) 99%
123333-53-
9
Fluka, GmbH, Buchs, 
Switzerland
2-(N-morpholino)ethanesulfonic acid 
(MES) ≥99% 4432-31-9
USB Corporation, 
Cleveland, Ohio
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Appendix A2: Mass spectrometry data of compounds described in Section 2.3
Compound 1: 2-((Tert-butoxycarbonyl)amino)ethyl ethyl malonate (1)
Figure A2.1.a: MALDI-TOF Spectrum of 1, Matrix: sinapinic acid, positive mode
Figure A2.1.b: MALDI-TOF Spectrum of 1, Matrix: sinapinic acid, positive mode
74
Compound 2: 3’-ethoxycarbonyl-3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)-
[1,2](C60-Ih)[5,6]fullerene (2)
Figure A2.2: MALDI-TOF Spectrum of 2, Matrix: trans-2-[3-(4-tert-Butylphenyl)-2-
methyl-2-propenylidene]malononitrile, positive mode
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Compound 3: Bis(2-acetoxy-1-acetoxymethylethylcarbamoyl)methane (3)
Figure A2.3.a: MALDI-TOF Spectrum of 3, Matrix: sinapinic acid, positive mode
Figure S2.3.b: MALDI-TOF Spectrum of 3, Matrix: sinapinic acid, positive mode
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Compound 4: 3’-ethoxycarbonyl -3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)- 
3 ' ' , 3 ' ' , 3 ' ' ' , 3 ' ' ' , 3 ' ' ' ' ,  3 ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ' ,  3 ' ' ' ' ' ' - d e c a - ( 2 - a c e t o x y - 1 -
a c e t o x y m e t h y l e t h y l c a r b a m o y l ) - 3 ' H , 3 ' ' H , 3 ' ' ' H , 3 ' ' ' ' H , 3 ' ' ' ' ' H , 3 ' ' ' ' ' ' H -
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (4)
Figure A2.4.a: MALDI-TOF Spectrum of 4, Matrix: trans-2-[3-(4-tert-Butylphenyl)-2-
methyl-2-propenylidene]malononitrile, positive mode
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Figure A2.4.b: MALDI-TOF Spectrum of 4, Matrix: trans-2-[3-(4-tert-Butylphenyl)-2-
methyl-2-propenylidene]malononitrile, positive mode
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Compound 5: 3’-ethoxycarbonyl-3’-((2-ammoniumethoxy)carbonyl)- 3'', 3'', 3''', 3''', 
3'''', 3'''', 3''''', 3''''', 3'''''', 3''''''-deca-(2-hydroxy-1-(hydroxymethyl)ethylcarbamoyl)-3'H, 
3''H, 3'''H, 3''''H, 3'''''H, 3''''''H-hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)
[5,6]fullerene monohydrochloride (5)
Figure A2.5: ESI-TOF Spectrum of 5, positive mode
Compound 6: Paclitaxel-2′-Succinate (6)
Figure A2.6: MALDI-TOF Spectrum of 6, Matrix: trans-2-[3-(4-tert-Butylphenyl)-2-
methyl-2-propenylidene]malononitrile, positive mode
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Compound 7: Serinol-C60-Paclitaxel-2’-Succinate Derivative (7)
Figure A2.7: ESI-TOF Spectrum of 7, positive mode
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Compound 8: Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (8)
Figure A2.8: MALDI-TOF Spectrum of 8, Matrix: trans-2-[3-(4-tert-Butylphenyl)-2-
methyl-2-propenylidene]malononitrile, positive mode
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Compound 9: Serinol-C60-Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (9)
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Figure A2.9: ESI-TOF Spectrum of 9, positive mode
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Compound 10: 3’, 3’’, 3’’, 3’’’, 3’’’, 3’’’’, 3’’’’, 3’’’’’, 3’’’’’, 3’’’’’’, 3’’’’’’-dodeca-(2-
hydroxy-1-{hydroxymethyl}ethylcarbamoyl)-3’H, 3’’H, 3’’’H, 3’’’’H, 3’’’’’H, 3’’’’’’ H-
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (10)
Figure A2.10: ESI-TOF Spectrum of 10, positive mode
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Appendix A3: Infrared spectroscopy data of compounds described in Section 2.3
Compound 1: 2-((Tert-butoxycarbonyl)amino)ethyl ethyl malonate (1)
Figure A3.1: Infrared Transmission Spectrum of 1
(1)
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Compound 2: 3’-ethoxycarbonyl-3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)-
[1,2](C60-Ih)[5,6]fullerene (2)
Figure A3.2: Infrared Transmission Spectrum of 2
(2)
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Compound 3: Bis(2-acetoxy-1-acetoxymethylethylcarbamoyl)methane (3)
Figure A3.3: Infrared Transmission Spectrum of 3
(3)
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Compound 4: 3’-ethoxycarbonyl -3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)- 
3 ' ' , 3 ' ' , 3 ' ' ' , 3 ' ' ' , 3 ' ' ' ' ,  3 ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ' ,  3 ' ' ' ' ' ' - d e c a - ( 2 - a c e t o x y - 1 -
a c e t o x y m e t h y l e t h y l c a r b a m o y l ) - 3 ' H , 3 ' ' H , 3 ' ' ' H , 3 ' ' ' ' H , 3 ' ' ' ' ' H , 3 ' ' ' ' ' ' H -
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (4)
Figure A3.4: Infrared Transmission Spectrum of 4
(4)
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Compound 5: 3’-ethoxycarbonyl -3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)- 
3 ' ' , 3 ' ' , 3 ' ' ' , 3 ' ' ' , 3 ' ' ' ' ,  3 ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ,  3 ' ' ' ' ' ' ,  3 ' ' ' ' ' ' - d e c a - ( 2 - a c e t o x y - 1 -
a c e t o x y m e t h y l e t h y l c a r b a m o y l ) - 3 ' H , 3 ' ' H , 3 ' ' ' H , 3 ' ' ' ' H , 3 ' ' ' ' ' H , 3 ' ' ' ' ' ' H -
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (5)
Figure A3.5.a: Infrared Transmission Spectrum of 5
Figure A3.5.b: Analysis of Infrared Spectrum of 5
(5)
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Figure A3.6.a: Infrared Transmission Spectrum of Paclitaxel
Figure A3.6.b: Analysis of Infrared Spectrum of Paclitaxel
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Figure A3.6.c: Infrared Transmission Spectrum of 6
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Figure A3.7: Infrared Transmission Spectrum of 7
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Figure A3.8.a: Infrared Transmission Spectrum of 8
Figure A3.8.b: Analysis of Infrared Spectrum of 8
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Compound 9: Serinol-C60-Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (9)
Figure A3.9.a: Infrared Transmission Spectrum of 9
Figure A3.9.b: Analysis of Infrared Spectrum of 9
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Compound 10: 3’, 3’’, 3’’, 3’’’, 3’’’, 3’’’’, 3’’’’, 3’’’’’, 3’’’’’, 3’’’’’’, 3’’’’’’-dodeca-(2-
hydroxy-1-{hydroxymethyl}ethylcarbamoyl)-3’H, 3’’H, 3’’’H, 3’’’’H, 3’’’’’H, 3’’’’’’ H-
hexacyclopropa[1,2:18,36:22,23:27,45:31,32:55,60](C60-Ih)[5,6]fullerene (10)
Figure A3.10: Infrared Transmission Spectrum of 10
(10)
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Appendix A4: 1H and 13C Nuclear Magnetic Resonance spectroscopy of compounds 
described in Section 2.3
Compound 1: 2-((Tert-butoxycarbonyl)amino)ethyl ethyl malonate (1)
Figure A4.1.a: 500 MHz 1H Spectrum of 1 in CDCl3, 32 Scans
Figure A4.1.b: 500 MHz 13C Spectrum of 1 in CDCl3, 128 Scans
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Compound 2: 3’-Ethoxycarbonyl-3’-((2-((tert-butoxycarbonyl)amino)ethoxy)carbonyl)-
[1,2](C60-Ih)[5,6]fullerene (2)
Figure A4.2.a: 500 MHz 1H Spectrum of 2 in CDCl3, 64 Scans
Figure A4.2.b: 500 MHz 13C Spectrum of 2 in CDCl3, 256 Scans
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Compound 3: Bis(2-acetoxy-1-acetoxymethylethylcarbamoyl)methane (3)
Figure A4.3.a: 500 MHz 1H Spectrum of 3 in CDCl3, 32 Scans
Figure A4.3.b: 500 MHz 13C Spectrum of 3 in CDCl3, 128 Scans
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Figure A4.4.a: 500 MHz 1H Spectrum of paclitaxel in CDCl3, 32 Scans
Figure A4.4.b: 500 MHz 13C Spectrum of paclitaxel in CDCl3, 256 Scans
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Compound 6: Paclitaxel-2′-succinate (6) 
Figure A4.5.a: 500 MHz 1H Spectrum of 6 in CDCl3, 64 Scans
Figure A4.5.b: 500 MHz 13C Spectrum of 6 in CDCl3, 512 Scans
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Compound 8: Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (8)
Figure A4.6.a: 500 MHz 1H Spectrum of 8 in CDCl3, 32 Scans
Figure A4.6.b: 500 MHz 13C Spectrum of 8 in CDCl3, 512 Scans
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Appendix A5: Mean intensities of measured hydrodynamic diameters for Serinol-C60-
Paclitaxel-2′-Poly(ethylene glycol) Ester Derivative (compound 9) and its synthetic 
precursors (compounds 5 and 8). The hydrodynamic diameters provided are an 
abbreviation of the data to include only those results which show a measurable significant 
intensity.
Hydrodynamic 
Diameter (nm)
Normalized Mean Intensity (%)
Compound 5 Compound 8 Compound 9
58.77
68.06
78.82
91.28
105.7
122.4
141.8
164.2
190.1
220.2
255
295.3
342
396.1
458.7
531.2
615.1
712.4
0 0 0.7
0 0 1.7
0.1 0 2.2
0.8 0 2
3.8 0 1.5
6.6 0 1.1
8.9 0.6 1.6
10.4 8.1 5.4
11.4 19.2 11.7
12.1 25.7 17.7
12.2 23.6 20.1
11.1 14.9 17.5
8.9 5.7 11.2
6.4 1.1 4.6
4 0 1
2.2 0 0
0.9 0 0
0.2 0 0
101
Appendix A6: Cell internalization results over time for the Gd@C60-(ZME-018) and 
Gd@C60-(MuIgG) immunoconjugates into A375m and T24 cell lines
Table A6.1: Experiment 1
Cells, mAbs, 
Incubation Period
Gd 
Concentration in 
Sample (ppt)1
Number of Cells Gd@C60+C60 per cell mAbs per cell
A375m, No mAb, 0 hr 0.0 (0.00) 6.75E+06 0.00E+00 0.00E+00
A375m, ZME-018, 1 hr 35.7 (0.98) 7.30E+06 4.46E+13 9.27E+12
A375m, ZME-018, 2 hr 97.5 (2.08) 9.50E+06 9.38E+13 1.95E+13
A375m, ZME-018, 4 hr 55.6 (2.63) 7.60E+06 6.68E+13 1.39E+13
A375m, ZME-018, 24 
hr 62.3 (1.32) 1.20E+07 4.75E+13 9.85E+12
A375m, MuIgG, 1 hr 20.6 (0.86) 7.50E+06 2.51E+13 5.25E+12
A375m, MuIgG, 2 hr 39.3 (1.45) 8.10E+06 4.43E+13 9.29E+12
A375m, MuIgG, 4 hr 43.7 (1.29) 1.08E+07 3.70E+13 7.75E+12
A375m, MuIgG, 24 hr 19.7 (0.28) 9.30E+06 1.93E+13 4.05E+12
T24, No mAb, 0 hr 0.0 (0.00) 5.70E+06 0.00E+00 0.00E+00
T24, ZME-018, 1 hr 5.1 (0.12) 6.05E+06 7.66E+12 1.59E+12
T24, ZME-018, 2 hr 33.3 (1.20) 9.10E+06 3.34E+13 6.94E+12
T24, ZME-018, 4 hr 24.0 (0.71) 9.80E+06 2.24E+13 4.64E+12
T24, ZME-018, 24 hr 13.9 (0.20) 9.80E+06 1.30E+13 2.69E+12
T24, MuIgG, 1 hr 17.9 (0.73) 6.40E+06 2.56E+13 5.36E+12
T24, MuIgG, 2 hr 24.1 (1.35) 6.20E+06 3.55E+13 7.45E+12
T24, MuIgG, 4 hr 34.3 (1.74) 9.90E+06 3.17E+13 6.65E+12
T24, MuIgG, 24 hr 28.2 (1.08) 1.14E+07 2.26E+13 4.74E+12
1) Gd3+-ion concentration in parts per trillion from the average of ten individual ICP-MS 
measurements per sample with the standard deviation in parentheses.
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Table A6.2: Experiment 2
Cells, mAbs, 
Incubation Period
Gd 
Concentration in 
Sample (ppt)1
Number of Cells Gd@C60+C60 per cell mAbs per cell
A375m, No mAb, 0 hr 0.0 (0.00) 6.65E+06 0.00E+00 0.00E+00
A375m, ZME-018, 1 hr 19.8 (0.38) 4.30E+06 4.19E+13 8.70E+12
A375m, ZME-018, 2 hr 36.9 (1.73) 3.60E+06 9.34E+13 1.94E+13
A375m, ZME-018, 4 hr 33.5 (1.32) 4.50E+06 6.79E+13 1.41E+13
A375m, ZME-018, 24 
hr 27.8 (0.90) 5.90E+06 4.31E+13 8.93E+12
A375m, MuIgG, 1 hr 18.6 (0.62) 6.55E+06 2.60E+13 5.38E+12
A375m, MuIgG, 2 hr 17.2 (0.39) 3.35E+06 4.69E+13 9.72E+12
A375m, MuIgG, 4 hr 23.9 (0.60) 5.85E+06 3.72E+13 7.72E+12
A375m, MuIgG, 24 hr 17.8 (0.89) 7.40E+06 2.20E+13 4.56E+12
T24, No mAb, 0 hr 0.0 (0.00) 1.43E+06 0.00E+00 0.00E+00
T24, ZME-018, 1 hr 1.9 (0.11) 2.12E+06 8.14E+12 1.69E+12
T24, ZME-018, 2 hr 14.5 (0.49) 3.30E+06 4.00E+13 8.30E+12
T24, ZME-018, 4 hr 11.6 (0.24) 3.38E+06 3.14E+13 6.50E+12
T24, ZME-018, 24 hr 3.6 (0.05) 2.32E+06 1.43E+13 2.96E+12
T24, MuIgG, 1 hr 10.2 (0.36) 3.15E+06 2.96E+13 6.14E+12
T24, MuIgG, 2 hr 11.1 (0.51) 2.55E+06 3.96E+13 8.22E+12
T24, MuIgG, 4 hr 9.1 (0.23) 2.75E+06 3.03E+13 6.29E+12
T24, MuIgG, 24 hr 8.6 (0.19) 3.25E+06 2.42E+13 5.03E+00
1) Gd3+-ion concentration in parts per trillion from the average of ten individual ICP-MS 
measurements per sample with the standard deviation in parentheses.
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Appendix A7: Mass (g) of murine test subjects through the course of in vivo treatment 
with paclitaxel derivatives
Day 1 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
18.95 16.06 19.17 15.57 16.55
19.23 17.54 16.38 20.18 19.85
18.37 17.87 14.25 18.22 16.71
17.67 16.18 17.91 15.63 17.82
18.13 18.03 15.97 18.56 17.83
18.8 15.97 20.03 17.16
18.525 16.94167 17.285 17.632 17.653333
18.585 16.86 17.145 18.22 17.49
0.5769489 0.970143 2.15584554 1.99744086 1.2029076
3.1144339 5.72637 12.4723491 11.3284985 6.8140536
Table A7.1: Mass of murine test subjects after Day 1 of in vivo treatment with paclitaxel 
derivatives
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Day 2 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
18.17 16.32 16.77 18.66 17.93
17.95 17.42 18.95 16.48 18.03
19.13 17.23 13.96 19.26 17.38
18.91 15.48 18.04 16.4 18.89
18.45 16.52 16.18 20.6 16.84
18.62 17.97 20.78 16.75
18.53833 16.82333 17.4466667 18.28 17.636667
18.535 16.875 17.405 18.66 17.655
0.44373 0.892876 2.3639938 1.82082399 0.8121987
2.393583 5.307364 13.5498307 9.96074392 4.605171
Table A7.2: Mass of murine test subjects after Day 2 of in vivo treatment with paclitaxel 
derivatives
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Day 3 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
17.5 16.97 18.5 18.52 16.74
17.92 17.19 14.05 18.71 17.24
18.79 16.58 16.22 17.16 19.26
18.14 15.51 19.66 18.03 18.13
18.76 17 17.26 16.31 16.54
18.04 14.63 15.66 17.44
18.19167 16.31333 16.8916667 17.746 17.558333
18.09 16.775 16.74 18.03 17.34
0.501774 1.021894 2.02135021 1.00181336 1.0044385
2.75826 6.264162 11.9665528 5.64529108 5.7205799
Table A7.3: Mass of murine test subjects after Day 3 of in vivo treatment with paclitaxel 
derivatives
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Day 4 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
17.76 15.52 16.84 17.68 19.41
18.69 14.4 15.75 18.6 17.53
18.05 16.78 19.61 16.67 16.9
17.02 16.42 14.42 16.2 18.55
17.38 16.3 15.93 17.8 17.44
18.11 16.56 17.94 16.16
17.835 15.99667 16.7483333 17.39 17.665
17.905 16.36 16.385 17.68 17.485
0.588175 0.892046 1.82784481 0.95535334 1.1616669
3.29787 5.576451 10.9135923 5.49369372 6.5760934
Table A7.4: Mass of murine test subjects after Day 4 of in vivo treatment with paclitaxel 
derivatives
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Day 5 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
18.69 15.46 15.6 16.35 19.79
18.2 13.76 17.98 17.25 17.16
17.85 16.83 15.93 17.69 17.57
17.91 16.09 17.2 18.58 17.32
17.52 16.26 16.28 16.21 18.34
17.66 16.55 19.76
17.97167 15.825 17.125 17.216 18.036
17.88 16.175 16.74 17.25 17.57
0.421398 1.1128836 1.55868855 0.98085677 1.0800602
2.344793 7.03244 9.10183096 5.69735576 5.9883576
Table A7.5: Mass of murine test subjects after Day 5 of in vivo treatment with paclitaxel 
derivatives
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Day 6 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
16.8 14.8 17.36 16.55 16.98
17.34 15.63 15.88 16.69 19.06
17.58 14.78 14.59 16.35 17.26
17.54 12.94 19.13 16.55 16.13
18.19 14.85 15.44 17.53 17.06
17.45 15.98 17.18
17.48333 14.83 16.5966667 16.734 17.298
17.495 14.825 16.53 16.55 17.06
0.447333 1.052464 1.62597253 0.46117242 1.0756486
2.558624 7.096856 9.7969825 2.75590067 6.2183411
Table A7.6: Mass of murine test subjects after Day 6 of in vivo treatment with paclitaxel 
derivatives
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Day 7 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
16.67 12.3 14.98 16.71 15.41
17.36 14.54 15.85 16.27 19.66
17.11 15.74 17.93 16.39 16.92
17.18 14.22 19.15 16.68 17.68
17.15 15.55 15.85 17.41
18.29 14.21 16.55
17.293333 14.42667 16.7183333 16.692 17.4175
17.165 14.38 16.2 16.68 17.3
0.5391351 1.23385 1.54526912 0.44308013 10.149521
3.1175893 8.552567 9.24296157 2.65444601 1.7677929
Table A7.7: Mass of murine test subjects after Day 7 of in vivo treatment with paclitaxel 
derivatives
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Day 8 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
16.65 13.88 16.29 16.51 14.78
17.47 15.7 18.3 16.87 17.23
17.15 14.28 15.14 15.75 18.36
17.16 14.36 16.4 17.52 19.62
18.27 15.61 17.15 17.13
17.2 12.56 19.66
17.31667 14.39833 17.1566667 16.756 17.4975
17.18 14.32 16.775 16.87 17.795
0.537165 1.168425 1.6102505 0.67251766 2.0579338
3.102014 8.115001 9.38556731 4.01359309 11.761302
Table A7.8: Mass of murine test subjects after Day 8 of in vivo treatment with paclitaxel 
derivatives
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Day 9 Treatment Groups for In Vivo Studies of Murine Subjects
Paclitaxel Abraxane Compound 
9
Compound 
10
PBS
(Control)
Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Mean
Median
Standard 
Deviation 
(Absolute)
Standard 
Deviation 
(%)
18.32 14.32 18.73 18.18 15.26
18.63 15.22 16.45 18.32 20.54
20.05 15.92 17.52 19.3 20.18
20.04 13.59 15.74 16.78 17.9
17.68 16.23 17.97 16.51
19.07 14.47 15.55
18.965 14.95833 16.9933333 17.818 18.47
18.85 14.845 16.985 18.18 19.04
0.9511414 1.012787 1.28035412 1.15841271 2.4384421
5.015246 6.770718 7.5344495 6.50136215 13.202177
Table A7.9: Mass of murine test subjects after Day 9 of in vivo treatment with paclitaxel 
derivatives
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Appendix A8: Chemicals and their related information used in Section 2.4
Reagent/Equipment Commercial Source
Dulbecco's Modified Eagle Medium 
(DMEM), High Glucose Life Technologies, Carlsbad, California
10% Fetal Bovine Serum
Atlanta Biologicals, Lawrenceville, 
Georgia
Minimum Essential Medium (MEM), Non-
Essential Amino Acids (1×) Life Technologies, Carlsbad, California
Minimum Essential Medium (MEM),Vitamin 
Solution (1×) Life Technologies, Carlsbad, California
Sodium Pyruvate (1×) Life Technologies, Carlsbad, California
96-Well Flat-Bottom Sterile Plates
Becton, Dickinson and Co., Franklin 
Lakes, New Jersey
Dulbecco’s Phosphate Buffered Saline (PBS) Life Technologies, Carlsbad, California
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